Data / Research funding / Breast Cancer
Breast Cancer: 2,730 NIH awards ($3B) to 444 organizations
2,730 NIH awards ($3B) in the NIH spending category Breast Cancer, to 444 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
The 500 largest of 2,730 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2025 | $41,720,565 | June 1, 1997 | November 30, 2025 | FERRIS, ROBERT L. | reporter.nih.gov |
| Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2025 | $32,609,322 | August 2, 2001 | June 30, 2027 | EBERLEIN, TIMOTHY J. | reporter.nih.gov |
| Kansas IDeA Network of Biomedical Research Excellence 5 | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $21,278,824 | September 18, 2001 | April 30, 2029 | WRIGHT, DOUGLAS E | reporter.nih.gov |
| Administrative Supplement to Cancer Center Support Grant (CCSG) | NIH | National Cancer Institute | 2021 to 2025 | $21,104,098 | September 1, 2025 | August 31, 2026 | BOUTROS, PAUL CHRISTOPHER | reporter.nih.gov |
| Life Course Cancer Epidemiology Cohort in Women | NIH | National Cancer Institute | 2021 to 2025 | $15,280,631 | June 1, 2013 | August 31, 2028 | ELIASSEN, A. HEATHER | reporter.nih.gov |
| P30 Administrative Supplement for Early-Onset Cancer Research: Repurposing orphan drugs for early-onset endometrial cancer | NIH | National Cancer Institute | 2021 to 2025 | $14,689,665 | August 8, 1997 | November 30, 2026 | PASCHE, BORIS | reporter.nih.gov |
| Georgetown University Lombardi Comprehensive Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2025 | $12,475,608 | July 1, 2025 | June 30, 2026 | WEINER, LOUIS M. | reporter.nih.gov |
| Center for Musculoskeletal Disease Research (CMDR) | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $11,683,826 | February 16, 2018 | January 31, 2028 | O'BRIEN, CHARLES A | reporter.nih.gov |
| Center for Pre-Clinical Cancer Research | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $11,277,290 | March 1, 2021 | February 28, 2027 | FRANCIS, JOSEPH | reporter.nih.gov |
| A Follow-up Study for Causes of Cancer in Black Women | NIH | National Cancer Institute | 2021 to 2025 | $11,271,706 | September 21, 2012 | August 31, 2027 | PALMER, JULIE R | reporter.nih.gov |
| Administrative Supplement for the NCI P30 CCSG to extend partnerships with comprehensive cancer control coalitions to study implementation of evidence-based cancer control interventions | NIH | National Cancer Institute | 2021 | $11,079,774 | January 1, 1997 | March 31, 2022 | LYNCH, THOMAS JAMES | reporter.nih.gov |
| MSK SPORE in Genomic Instability in Breast Cancer | NIH | National Cancer Institute | 2021 to 2025 | $10,402,609 | August 13, 2020 | July 31, 2026 | POWELL, SIMON N. | reporter.nih.gov |
| Kansas Center for Metabolism and Obesity REsearch (KC-MORE) | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $10,233,525 | April 1, 2022 | February 28, 2027 | WEINMAN, STEVEN A | reporter.nih.gov |
| Translational Research in Breast Cancer | NIH | National Cancer Institute | 2021 to 2025 | $9,097,808 | September 19, 2014 | July 31, 2026 | ZHANG, XIANG | reporter.nih.gov |
| Comparative Modeling of Precision Breast Cancer Control Across the Translational Continuum Administrative Supplement | NIH | National Cancer Institute | 2021 to 2025 | $8,668,837 | September 1, 2020 | August 31, 2026 | TRENTHAM-DIETZ, AMY | reporter.nih.gov |
| Infrastructure for Pathways, a Prospective Study of Breast Cancer Survivorship | NIH | National Cancer Institute | 2021 to 2025 | $8,656,392 | June 1, 2016 | May 31, 2027 | KUSHI, LAWRENCE H | reporter.nih.gov |
| Breast Cancer Family Registry | NIH | National Cancer Institute | 2021 to 2025 | $8,625,718 | September 12, 2012 | April 30, 2028 | TERRY, MARY BETH | reporter.nih.gov |
| Center of Biomedical Research Excellence in Matrix Biology Phase II | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $8,248,947 | August 1, 2014 | May 31, 2025 | OXFORD, JULIA THOM | reporter.nih.gov |
| Extending the Diversity, Reach, and Generalizability of the WISDOM Study | NIH | National Cancer Institute | 2021 to 2024 | $7,580,298 | March 1, 2020 | February 28, 2026 | ESSERMAN, LAURA J | reporter.nih.gov |
| SPORE in Breast Cancer | NIH | National Cancer Institute | 2021 to 2024 | $7,513,457 | August 1, 2024 | July 31, 2025 | PIETENPOL, JENNIFER A | reporter.nih.gov |
| WOMEN'S HEALTH INITIATIVE (WHI) REGIONAL CENTER (RC): TASK AREA A AND A2 | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $6,882,445 | September 29, 2025 | September 28, 2026 | WACTAWSKI-WENDE, JEAN | reporter.nih.gov |
| Washington University/Siteman Cancer Center Lead Academic Site | NIH | National Cancer Institute | 2021 to 2025 | $6,572,668 | March 5, 2019 | February 28, 2026 | BARTLETT, NANCY L | reporter.nih.gov |
| WOMEN'S HEALTH INITIATIVE (WHI) REGIONAL CENTER (RC): TASK AREA A AND A2 | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $6,534,889 | September 29, 2025 | September 28, 2026 | STEFANICK, MARCIA | reporter.nih.gov |
| PhytoSERM Efficacy to Prevent Menopause Associated Decline in Brain Metabolism and Cognition: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Trial | NIH | National Institute on Aging | 2022 to 2025 | $6,295,083 | February 15, 2022 | January 31, 2027 | BRINTON, ROBERTA EILEEN | reporter.nih.gov |
| Essentia Health Community Cancer Research Program - NCORP | NIH | National Cancer Institute | 2021 to 2025 | $5,823,202 | August 9, 2014 | July 31, 2026 | FRIDAY, BRET E.B. | reporter.nih.gov |
| Finding Sleeping Beauty: T Cell Biosensors for Dormant Cancer Detection | NIH | National Cancer Institute | 2022 to 2025 | $5,481,630 | September 20, 2022 | August 31, 2027 | KWONG, GABRIEL A | reporter.nih.gov |
| NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care | NIH | National Cancer Institute | 2021 to 2025 | $5,422,908 | March 5, 2019 | February 28, 2026 | BURSTEIN, HAROLD JOHN | reporter.nih.gov |
| Targeting intratumor heterogeneity in breast cancer | NIH | National Cancer Institute | 2021 to 2025 | $5,301,919 | August 1, 2015 | July 31, 2029 | POLYAK, KORNELIA | reporter.nih.gov |
| Optimizing the use of ketamine to reduce chronic postsurgical pain | NIH | National Cancer Institute | 2021 to 2024 | $5,247,593 | September 17, 2021 | August 31, 2025 | WANG, JING | reporter.nih.gov |
| Tracking the evolution of breast cancer through single cell analyses of premalignant breast tissues from women at high risk for cancer development | NIH | National Cancer Institute | 2021 to 2025 | $5,046,546 | September 1, 2019 | August 31, 2026 | BRUGGE, JOAN SIEFERT | reporter.nih.gov |
| Integrating targeted therapy and immunotherapy to break through cancer | NIH | National Cancer Institute | 2021 to 2025 | $5,025,838 | September 1, 2016 | August 31, 2030 | ZHAO, JEAN | reporter.nih.gov |
| Homology-directed repair: BRCA2 and RAD51 paralogs | NIH | National Cancer Institute | 2021 to 2025 | $5,007,139 | August 1, 2020 | July 31, 2027 | JASIN, MARIA | reporter.nih.gov |
| WOMEN'S HEALTH INITIATIVE (WHI) REGIONAL CENTER (RC): TASK AREA A AND A2 | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $5,000,825 | September 29, 2025 | September 28, 2026 | JACKSON, REBECCA | reporter.nih.gov |
| Determine the molecular and metabolic mechanisms by which A-FABP links dysregulated lipid metabolism-induced obesity/breast cancer risk | NIH | National Cancer Institute | 2022 to 2025 | $4,769,593 | August 12, 2022 | July 31, 2027 | LI, BING | reporter.nih.gov |
| TeleHealth Resistance exercise Intervention to preserve dose intensity and Vitality in Elder breast cancer patients (THRIVE) | NIH | National Cancer Institute | 2022 to 2025 | $4,496,377 | December 19, 2022 | March 31, 2027 | SCHMITZ, KATHRYN H. | reporter.nih.gov |
| Germline variation in homologous recombination repair genes in Hispanic/Latina women to predict breast cancer risk and response to treatment | NIH | National Institute on Minority Health and Health Disparities | 2025 | $4,307,388 | September 1, 2025 | June 30, 2029 | ZIV, ELAD | reporter.nih.gov |
| WOMEN'S HEALTH INITIATIVE (WHI) REGIONAL CENTER (RC): TASK AREA A AND A2 | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $4,249,024 | September 29, 2025 | September 28, 2026 | VITOLINS, MARA | reporter.nih.gov |
| Tumor Immune Contexture and Breast Cancer Disparities: A Multi-Disciplinary Study in Women of African and European Ancestry | NIH | National Cancer Institute | 2021 to 2024 | $4,181,635 | June 1, 2020 | May 31, 2025 | AMBROSONE, CHRISTINE B. | reporter.nih.gov |
| Biomarker-Based Phase IIB Trial of (Bazedoxifene-Conjugated Estrogen) to Reduce Risk for Breast Cancer | NIH | National Cancer Institute | 2021 to 2025 | $4,143,666 | February 26, 2021 | July 31, 2027 | FABIAN, CAROL J. | reporter.nih.gov |
| Insights from Asian Populations into Disparities in Breast Cancer Prognosis and Outcomes | NIH | National Cancer Institute | 2021 to 2024 | $4,137,490 | June 8, 2020 | May 31, 2026 | GOMEZ, SCARLETT L | reporter.nih.gov |
| Flexible versus Standard Aerobic Training Dosing in Primary Breast Cancer: A Randomized and Response-Adapted Trial | NIH | National Cancer Institute | 2022 to 2025 | $4,082,444 | September 21, 2022 | August 31, 2027 | SCOTT, JESSICA | reporter.nih.gov |
| Determining the contribution of microbial-derived metabolites to protective immunity in obesity-driven cancer risk. | NIH | National Cancer Institute | 2022 to 2025 | $4,079,710 | September 1, 2022 | August 31, 2027 | MAKOWSKI-HAYES, LIZA | reporter.nih.gov |
| Stalled replication fork repair in cancer predisposition and cancertherapy | NIH | National Cancer Institute | 2022 to 2025 | $4,040,847 | August 10, 2022 | July 31, 2029 | SCULLY, RALPH | reporter.nih.gov |
| Chronic Social Stressors and Biological Embodiment of Risk in Breast Cancer Mortality | NIH | National Cancer Institute | 2022 to 2025 | $3,981,466 | September 23, 2022 | August 31, 2027 | AKINYEMIJU, TOMI F | reporter.nih.gov |
| Resolving the cancer relevance of predisposition gene mutations | NIH | National Cancer Institute | 2021 to 2025 | $3,942,823 | September 1, 2020 | August 31, 2027 | COUCH, FERGUS JOSEPH | reporter.nih.gov |
| Commercial Readiness for Direct-to-Digital Pathology | NIH | National Cancer Institute | 2023 to 2025 | $3,934,777 | January 1, 2024 | August 31, 2027 | LEVENE, MICHAEL JOHN | reporter.nih.gov |
| Quantitative Imaging Clinical Validation Center at Moffitt Cancer Center | NIH | National Cancer Institute | 2021 to 2025 | $3,928,528 | July 22, 2016 | August 31, 2028 | HEINE, JOHN J | reporter.nih.gov |
| A physical sciences approach to investigate the role of exosomes in metastatic progression | NIH | National Cancer Institute | 2021 to 2025 | $3,903,970 | September 16, 2021 | August 31, 2026 | RADHAKRISHNAN, RAVI | reporter.nih.gov |
| Bay Area Cancer Target Discovery and Development | NIH | National Cancer Institute | 2022 to 2025 | $3,880,946 | September 13, 2022 | August 31, 2027 | MCMANUS, MICHAEL T | reporter.nih.gov |
| Somatic Mutations and Their Etiological Determinants for Breast Cancer in African American Women | NIH | National Cancer Institute | 2021 to 2023 | $3,873,758 | February 1, 2019 | January 31, 2026 | YAO, SONG | reporter.nih.gov |
| High-speed panoramic 3D photoacoustic computed tomography of the breast | NIH | National Cancer Institute | 2021 to 2024 | $3,869,748 | August 1, 2018 | July 31, 2025 | WANG, LIHONG | reporter.nih.gov |
| Randomized Phase II Trial of Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women with Hormone Receptor Positive Advanced Breast Cancer (FastER) | NIH | National Cancer Institute | 2023 to 2025 | $3,777,161 | September 20, 2023 | August 31, 2028 | CRANE, TRACY E | reporter.nih.gov |
| Fred Hutchinson Breast Cancer Clinical Validation Center | NIH | National Cancer Institute | 2022 to 2025 | $3,773,783 | August 16, 2010 | July 31, 2027 | LI, CHRISTOPHER I | reporter.nih.gov |
| Columbus NCORP RFA-CA-18-016 | NIH | National Cancer Institute | 2021 to 2025 | $3,771,688 | August 1, 2014 | July 31, 2026 | RAJAGOPALAN, MALOLAN S | reporter.nih.gov |
| Rational Integration of Polygenic Risk Scores (RIPS) | NIH | National Human Genome Research Institute | 2022 to 2025 | $3,737,256 | March 10, 2022 | February 28, 2027 | PETERSON, JOSEPH F. | reporter.nih.gov |
| The Funding Mechanism of the Pilot Trial | NIH | National Cancer Institute | 2023 to 2025 | $3,690,580 | August 11, 2023 | July 31, 2028 | OLOPADE, OLUFUNMILAYO F. | reporter.nih.gov |
| Mechanism of estrogen independent proliferation in ER+ breast cancer cells | NIH | National Cancer Institute | 2021 to 2025 | $3,641,042 | September 1, 2021 | August 31, 2027 | BILD, ANDREA HOPE | reporter.nih.gov |
| Effectiveness and implementation of a health system intervention to improve quality of cancer care for rural, underserved patients | NIH | National Cancer Institute | 2021 to 2025 | $3,568,895 | April 1, 2021 | March 31, 2027 | CHARLTON, MARY E. | reporter.nih.gov |
| Breast White Adipose Tissue Inflammation and Breast Cancer Outcomes | NIH | National Cancer Institute | 2021 to 2024 | $3,529,677 | May 1, 2020 | April 30, 2026 | KUSHI, LAWRENCE H | reporter.nih.gov |
| Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers | NIH | National Cancer Institute | 2021 to 2025 | $3,519,313 | July 12, 2021 | June 30, 2026 | DUCKETT, DEREK RONALD | reporter.nih.gov |
| Nutrition and Physical Activity Assessment Study (NPAAS) | NIH | National Cancer Institute | 2021 to 2025 | $3,492,459 | July 12, 2006 | June 30, 2028 | NEUHOUSER, MARIAN L | reporter.nih.gov |
| Genomic Biology of the Tandem Duplicator Phenotype in Mouse and Human Cancers | NIH | National Cancer Institute | 2021 to 2025 | $3,456,605 | December 1, 2020 | November 30, 2025 | LIU, EDISON TAK-BUN | reporter.nih.gov |
| Evaluation of risk-based supplemental ultrasound and MRI screening strategies for women with dense breasts | NIH | National Cancer Institute | 2021 to 2025 | $3,450,916 | March 1, 2020 | July 31, 2030 | SPRAGUE, BRIAN L | reporter.nih.gov |
| Multi-modal Liquid Biopsy Early Assessment of Breast Cancer, Pancreatic Cancer, and Multiple Myeloma | NIH | National Cancer Institute | 2023 to 2025 | $3,449,390 | September 18, 2023 | August 31, 2028 | KUHN, PETER | reporter.nih.gov |
| Impact of Circulating Myeloid Cell Clusters on Anti-Tumor Immunity | NIH | National Cancer Institute | 2021 to 2025 | $3,445,316 | January 1, 2021 | December 31, 2026 | EVANS, SHARON S | reporter.nih.gov |
| Enhancing the public health benefits of mammography screening by informing women of both breast cancer and breast arterial calcification results: A randomized trial to promote cardiovascular health | NIH | National Cancer Institute | 2021 to 2025 | $3,435,650 | April 1, 2022 | March 31, 2027 | MONTGOMERY, GUY H | reporter.nih.gov |
| Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous system | NIH | National Cancer Institute | 2021 to 2025 | $3,433,365 | July 1, 2021 | June 30, 2027 | BOTA, DANIELA ANNENELIE | reporter.nih.gov |
| Chemical tools for developmental biology | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,426,216 | April 1, 2018 | June 30, 2028 | CHEN, JAMES K | reporter.nih.gov |
| Radiomics and Pathomics to predict upstaging of DCIS | NIH | National Cancer Institute | 2021 to 2025 | $3,369,053 | May 1, 2021 | April 30, 2026 | NIELL, BETHANY LYNN | reporter.nih.gov |
| A Randomized Trial to Minimize Non-Response to Aerobic Training in Operable Breast Cancer | NIH | National Cancer Institute | 2021 to 2025 | $3,359,060 | April 1, 2025 | March 31, 2027 | SCOTT, JESSICA | reporter.nih.gov |
| UNITS: The UNC / UT National Clinical Trials Network Group Integrated Translational Science Production and Consultation Center | NIH | National Cancer Institute | 2021 to 2025 | $3,358,438 | March 13, 2019 | February 28, 2026 | MERKER, JASON DEREK | reporter.nih.gov |
| DNA Methylation Markers, Genes and Breast Cancer Risk | NIH | National Cancer Institute | 2021 to 2025 | $3,357,930 | April 1, 2021 | March 31, 2027 | LONG, JIRONG | reporter.nih.gov |
| Evaluating the Impact of Accessible and Scalable Digital Interventions to Address Co-Occurring Insomnia and Depression in Breast Cancer Survivors Using an Adaptive Design | NIH | National Cancer Institute | 2025 | $3,355,681 | September 24, 2025 | August 31, 2029 | CHOW, PHILIP | reporter.nih.gov |
| Career Development in Pediatric and Medical Oncology | NIH | National Cancer Institute | 2021 to 2025 | $3,314,336 | September 30, 1997 | August 31, 2026 | MESHINCHI, SOHEIL | reporter.nih.gov |
| Stroger Hospital of Cook County (SHCC) MU-NCORP Renewal | NIH | National Cancer Institute | 2021 to 2024 | $3,305,824 | August 16, 2014 | March 31, 2025 | TAMKUS, DEIMANTE | reporter.nih.gov |
| Strategy for combining circulating tumor DNA (ctDNA) and magnetic resonance imaging (MRI) measures of tumor burden for prediction of response and outcome in neoadjuvant-treated early breast cancer | NIH | National Cancer Institute | 2021 to 2025 | $3,290,798 | December 3, 2020 | November 30, 2026 | VAN'T VEER, LAURA J | reporter.nih.gov |
| Biomarkers to Improve Targeting of Breast Cancer Prevention in Women with Atypical Hyperplasia | NIH | National Cancer Institute | 2021 to 2024 | $3,277,143 | January 1, 2020 | December 31, 2024 | DEGNIM, AMY C | reporter.nih.gov |
| Machine learning for risk-adjusted breast MRI screening | NIH | National Cancer Institute | 2021 to 2025 | $3,271,723 | December 9, 2020 | November 30, 2026 | PARRA, LUCAS C | reporter.nih.gov |
| TMEM, MENAcalc, and MENAINV as Prognostic and Predictive Markers for Breast Cancer Metastasis | NIH | National Cancer Institute | 2021 to 2024 | $3,213,083 | July 1, 2020 | June 30, 2025 | ROHAN, THOMAS E | reporter.nih.gov |
| Therapeutic Targeting of RNA Splicing in Triple-Negative Breast Cancer | NIH | National Cancer Institute | 2021 to 2025 | $3,199,527 | February 5, 2018 | May 31, 2028 | WESTBROOK, THOMAS | reporter.nih.gov |
| Synergized Immune and Tumor Cell Bone Marrow Biomarkers to Predict Recurrence in Triple Negative Breast Cancer | NIH | National Cancer Institute | 2021 to 2025 | $3,185,429 | September 21, 2021 | August 31, 2026 | AFT, REBECCA L. | reporter.nih.gov |
| Washington University Co-Clinical Imaging Research Resource | NIH | National Cancer Institute | 2021 to 2025 | $3,181,348 | March 17, 2017 | July 31, 2027 | SHOGHI, KOORESH ISAAC | reporter.nih.gov |
| Deepening optical imaging with next-generation photoacoustic computed tomography | NIH | National Institute on Drug Abuse | 2025 | $3,179,146 | September 1, 2025 | August 31, 2027 | WANG, LIHONG | reporter.nih.gov |
| High-flow microfluidics of leukapheresis blood products for functional analysis of breast circulating tumor cells | NIH | National Cancer Institute | 2021 to 2025 | $3,174,261 | January 8, 2021 | December 31, 2025 | TONER, MEHMET | reporter.nih.gov |
| Precision magnetic hyperthermia by integrating magnetic particle imaging | NIH | National Cancer Institute | 2021 to 2025 | $3,163,595 | July 1, 2021 | June 30, 2027 | BULTE, JEFF W. | reporter.nih.gov |
| Lesion Composition and Quantitative Imaging Analysis on Breast Cancer Diagnosis | NIH | National Cancer Institute | 2021 to 2025 | $3,160,598 | August 9, 2021 | July 31, 2027 | SHEPHERD, JOHN ALAN | reporter.nih.gov |
| Understanding affective processing of scientific evidence to promote informed choice for breast cancer screening | NIH | National Cancer Institute | 2021 to 2025 | $3,151,517 | February 1, 2021 | January 31, 2026 | SCHERER, LAURA D. | reporter.nih.gov |
| FEN1 Endonuclease as a Synthetic Lethal Target for Cancer Therapy | NIH | National Cancer Institute | 2021 to 2025 | $3,139,888 | August 15, 2021 | July 31, 2027 | KOLODNER, RICHARD D | reporter.nih.gov |
| Abbreviated Non-Contrast-Enhanced MRI for Breast Cancer Screening | NIH | National Cancer Institute | 2021 to 2025 | $3,129,089 | February 1, 2021 | January 31, 2027 | HARGREAVES, BRIAN ANDREW | reporter.nih.gov |
| Investigating Environmental Risk Factors for Breast Cancer Using Adductomics | NIH | National Institute of Environmental Health Sciences | 2021 to 2025 | $3,128,545 | March 11, 2021 | December 31, 2026 | FUNK, WILLIAM E | reporter.nih.gov |
| MADRE (Mammograms Available Due to Research and Education) | NIH | National Cancer Institute | 2022 to 2025 | $3,116,172 | September 1, 2025 | August 31, 2027 | MOLINA, YAMILE | reporter.nih.gov |
| Small molecule enhancers of tumor immunity targeting the LPA5 GPCR | NIH | National Cancer Institute | 2022 to 2025 | $3,114,085 | August 1, 2022 | July 31, 2026 | TIGYI, GABOR J | reporter.nih.gov |
| FFNP-PET as a predictive biomarker of response to endocrine therapy approaches in advanced breast cancer | NIH | National Cancer Institute | 2022 to 2025 | $3,111,179 | September 1, 2022 | August 31, 2027 | SHOGHI, KOORESH ISAAC | reporter.nih.gov |
| Cancer Pain Management: A Technology-Based Intervention for Asian American Breast Cancer Survivors | NIH | National Cancer Institute | 2023 to 2025 | $3,108,577 | September 20, 2022 | August 31, 2027 | IM, EUN-OK | reporter.nih.gov |
| A Randomized Hybrid Type I effectiveness-implementation study of an Ehealth delivery Alternative for Cancer genetic testing for Hereditary cancer predisposition (eREACH) | NIH | National Cancer Institute | 2021 to 2024 | $3,102,890 | September 17, 2020 | August 31, 2025 | BRADBURY, ANGELA R. | reporter.nih.gov |
| In Situ Albumin Binding siRNAs for Triple Negative Breast Cancer Tumor Penetration and Molecularly Targeted Therapy | NIH | National Cancer Institute | 2021 to 2025 | $3,035,458 | July 5, 2021 | June 30, 2027 | DUVALL, CRAIG LEWIS | reporter.nih.gov |
| Validation of a novel 3D culture platform for TNBC treatment selection | NIH | National Cancer Institute | 2022 to 2025 | $3,027,149 | September 20, 2022 | August 31, 2027 | YUN, KYUSON | reporter.nih.gov |
| Stem Cell Biology, Cancer Stem Cell Biology, and Cancer Immunotherapy | NIH | National Cancer Institute | 2021 to 2023 | $3,015,518 | September 21, 2017 | August 31, 2024 | WEISSMAN, IRVING L. | reporter.nih.gov |
| LISTOS for Cancer Control - Leveraging Implementation Science To Optimize Strategies for Cancer Control | NIH | National Cancer Institute | 2023 to 2025 | $3,009,659 | September 20, 2023 | August 31, 2028 | FERNANDEZ, MARIA EULALIA | reporter.nih.gov |
| Precision Imaging of Breast Cancer for Guiding Neoadjuvant Endocrine Therapy | NIH | National Cancer Institute | 2022 to 2025 | $3,008,001 | September 20, 2022 | August 31, 2028 | FOWLER, AMY | reporter.nih.gov |
| Targeting RANK Pathway in Mammographic Density and Primary Breast Cancer Prevention | NIH | National Cancer Institute | 2021 to 2025 | $3,007,238 | August 5, 2019 | July 31, 2027 | TORIOLA, ADETUNJI T | reporter.nih.gov |
| Mechanisms of Genome Integrity | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,001,194 | May 1, 2016 | April 30, 2027 | GREENE, ERIC C | reporter.nih.gov |
| Role of FSH in postmenopausal obesity and breast cancer | NIH | National Cancer Institute | 2022 to 2025 | $3,000,333 | March 1, 2022 | February 28, 2027 | BEA, JENNIFER WRIGHT | reporter.nih.gov |
| Satisfaction of Search in Breast Cancer Detection | NIH | National Cancer Institute | 2021 to 2025 | $2,997,422 | March 15, 2021 | February 28, 2027 | MELLO-THOMS, CLAUDIA R | reporter.nih.gov |
| Writing to Heal: A Culturally Based Brief Expressive Writing Intervention for Chinese Immigrant Breast Cancer Survivors | NIH | National Cancer Institute | 2021 to 2025 | $2,983,485 | July 1, 2021 | June 30, 2027 | LU, QIAN | reporter.nih.gov |
| Minerals in Nutrition and Development | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 to 2025 | $2,946,652 | August 7, 2023 | June 30, 2028 | RAO, RAJINI | reporter.nih.gov |
| Effectiveness and implementation of a decision support tool to improve surgical decision making in young women with breast cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,933,777 | September 1, 2025 | August 31, 2027 | ROSENBERG, SHOSHANA M | reporter.nih.gov |
| P53, DNA Repair Imbalance, and Immune Response in Breast Cancer Mortality Disparities | NIH | National Cancer Institute | 2021 to 2025 | $2,933,491 | April 6, 2021 | July 31, 2026 | TROESTER, MELISSA A. | reporter.nih.gov |
| Enhanced BReast and cErvical cAncer screening in Kenya THROUGH implementation science research and training (The BREAKTHROUGH Center) | NIH | National Cancer Institute | 2023 to 2025 | $2,931,308 | September 19, 2023 | August 31, 2028 | CHUNG, MICHAEL HOONBAE | reporter.nih.gov |
| Improving our understanding of breast cancer mortality disparities through recurrence: a multi-level approach among women in Georgia | NIH | National Cancer Institute | 2021 to 2025 | $2,928,200 | March 4, 2021 | February 28, 2027 | MCCULLOUGH, LAUREN E | reporter.nih.gov |
| The EPICS (Engaging Primary care in Cancer Survivorship) study: A trial of novel models of care for cancer survivors | NIH | National Cancer Institute | 2021 to 2024 | $2,922,559 | June 1, 2020 | September 30, 2025 | HAHN, ERIN ELIZABETH | reporter.nih.gov |
| Molecular Imaging and Theranostics of Cancer | NIH | National Cancer Institute | 2021 to 2023 | $2,907,093 | September 4, 2017 | March 31, 2025 | BHUJWALLA, ZAVER M. | reporter.nih.gov |
| Breast Cancer PARP PET Imaging AIP to Support FDA Approval & Commercialization | NIH | National Cancer Institute | 2021 to 2025 | $2,907,069 | March 24, 2021 | February 28, 2026 | MANKOFF, DAVID A. | reporter.nih.gov |
| Functional Significance of individual p53 mutations in determining the role of estrogen receptor beta in triple negative breast cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,894,996 | March 1, 2021 | February 28, 2027 | DAS, GOKUL M. | reporter.nih.gov |
| Targeting centrosome‐mitotic kinases as a novel therapeutic approach against breast cancers in Hispanic/Latinas. | NIH | National Cancer Institute | 2022 to 2025 | $2,894,071 | September 15, 2022 | August 31, 2027 | SAAVEDRA, HAROLD I | reporter.nih.gov |
| Tumor Endothelial Cell Regulation of Pro-Metastatic Fibrin Matrices | NIH | National Cancer Institute | 2021 to 2025 | $2,877,928 | March 1, 2021 | February 28, 2026 | PECOT, CHAD V | reporter.nih.gov |
| Modeling the role and regulation of reactive stroma in breast ductal carcinoma microinvasions | NIH | National Cancer Institute | 2022 to 2025 | $2,877,838 | September 1, 2022 | August 31, 2027 | REJNIAK, KATARZYNA ANNA | reporter.nih.gov |
| Tumor selective inhibition of the WNT pathway | NIH | National Cancer Institute | 2022 to 2025 | $2,875,859 | September 22, 2022 | August 31, 2027 | DOW, LUKAS EDWARD | reporter.nih.gov |
| The IMproving Access to Genetic INformation for Everyone (IMAGINE) Study: A Prospective Trial of a Mainstreaming Model for Hereditary Cancer Multigene Panel Testing Among Cancer Patients | NIH | National Cancer Institute | 2021 to 2025 | $2,867,395 | September 16, 2020 | August 31, 2027 | HAMILTON, JADA GABRIELLE | reporter.nih.gov |
| Overcoming hypoxic resistance to anti-cancer therapy | NIH | National Cancer Institute | 2021 to 2025 | $2,861,132 | December 15, 2020 | May 31, 2026 | DENKO, NICHOLAS C. | reporter.nih.gov |
| Increasing Engagement in Patient Reported Outcome Measurement to Improve Breast Cancer Care using Health Information Technology in Community Cancer Settings | NIH | National Cancer Institute | 2023 to 2025 | $2,859,863 | September 21, 2023 | August 31, 2027 | PUSIC, ANDREA LOUISE | reporter.nih.gov |
| Characterization and prevention of Chemotherapy-Induced Damage to Ovarian Reserve | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2025 | $2,852,424 | September 15, 2007 | January 31, 2027 | OKTAY, KUTLUK H | reporter.nih.gov |
| Estrogen receptor fusions genes as drivers of endocrine resistance in breast cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,849,181 | April 1, 2021 | March 31, 2026 | LEE, ADRIAN V | reporter.nih.gov |
| Impact of CAR and Nrf2 dual activation on cyclophosphamide bioactivation and doxorubicin detoxification | NIH | National Cancer Institute | 2025 | $2,840,768 | August 18, 2025 | July 30, 2029 | WANG, HONGBING | reporter.nih.gov |
| Effect and Mechanism of Acupuncture for Cancer-related Cognitive Impairment (ENHANCE) | NIH | National Cancer Institute | 2021 to 2024 | $2,818,159 | June 1, 2020 | May 31, 2025 | MAO, JUN J | reporter.nih.gov |
| Discovering the role of YES1 in triple negative breast cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,805,224 | February 1, 2021 | January 31, 2027 | KERI, RUTH A. | reporter.nih.gov |
| Body composition and breast cancer survival: immune and metabolic biomarkers in breast tumors | NIH | National Cancer Institute | 2021 to 2025 | $2,800,328 | July 1, 2020 | June 30, 2027 | FELICIANO, ELIZABETH MARJORIE CESPEDES | reporter.nih.gov |
| Ecology and Evolution of Breast Carcinogenesis | NIH | National Cancer Institute | 2021 to 2025 | $2,794,274 | September 15, 2021 | August 31, 2027 | DAMAGHI, MEHDI | reporter.nih.gov |
| A premalignant chronology of cell-state variability in basal-like breast cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,790,901 | January 1, 2022 | December 31, 2026 | JANES, KEVIN A | reporter.nih.gov |
| anti-miR-10b Nanodrug for Treatment of Breast Cancer Metastasis: Study in Companion Animals | NIH | National Cancer Institute | 2021 to 2025 | $2,789,961 | July 13, 2021 | June 30, 2027 | MOORE, ANNA | reporter.nih.gov |
| Subclonal heterogeneity and outcome disparities in Triple-Negative Breast Cancer among African Americans | NIH | National Cancer Institute | 2022 to 2025 | $2,785,523 | April 1, 2022 | March 31, 2027 | ELLISEN, LEIF W | reporter.nih.gov |
| A Randomized Controlled Trial: Genetic Counseling Patient Preference Intervention via Electronic Health Record Portal vs. Conventional Genetic Counseling for Women at Elevated Risk for Breast Cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,781,114 | January 1, 2021 | December 31, 2026 | SWEET, KEVIN M. | reporter.nih.gov |
| Testing a narrative intervention to enhance genetic counseling and testing | NIH | National Cancer Institute | 2021 to 2025 | $2,779,646 | January 1, 2021 | December 31, 2025 | HURTADO DE MENDOZA CASAUS, ALEJANDRA | reporter.nih.gov |
| Academic-Industrial Partnership for Translation of Acoustic Angiography | NIH | National Cancer Institute | 2021 to 2025 | $2,774,949 | September 4, 2014 | August 31, 2027 | DAYTON, PAUL A | reporter.nih.gov |
| Developmental Exposures, Stem Cell Reprogramming, and Breast Cancer Disparities | NIH | National Institute of Environmental Health Sciences | 2021 to 2025 | $2,767,677 | January 1, 2018 | October 31, 2027 | COLACINO, JUSTIN ADAM | reporter.nih.gov |
| Molecular ontology of drug tolerant persisters in HER2 positive breast cancer - Resubmission - 1 | NIH | National Cancer Institute | 2022 to 2025 | $2,763,196 | January 1, 2022 | December 31, 2026 | SKOK, JANE AMANDA | reporter.nih.gov |
| Remotely-Delivered Cognitive Behavioral Stress Management Effects on Cancer-Accelerated Aging in Older, Distressed Breast Cancer Survivors | NIH | National Cancer Institute | 2025 | $2,746,080 | September 12, 2025 | August 31, 2029 | ANTONI, MICHAEL HOWARD | reporter.nih.gov |
| Credentialing Models of Invasive Lobular Breast Cancer for Translational Research | NIH | National Cancer Institute | 2021 to 2025 | $2,743,261 | April 1, 2021 | March 31, 2027 | OESTERREICH, STEFFI | reporter.nih.gov |
| Minibeam Radiation Therapy Enhanced Delivery of Nanoparticle Anticancer Agents to Pancreatic Cancer Tumors | NIH | National Cancer Institute | 2021 to 2025 | $2,742,888 | April 1, 2021 | March 31, 2027 | ZAMBONI, WILLIAM C | reporter.nih.gov |
| Hexokinase 2 and cancer therapy | NIH | National Cancer Institute | 2021 to 2025 | $2,734,879 | July 1, 2021 | June 30, 2027 | HAY, NISSIM | reporter.nih.gov |
| Can risk-reducing medications improve breast cancer prevention in childhood and adolescent cancer survivors? Comparative modeling to inform care | NIH | National Cancer Institute | 2022 to 2025 | $2,726,647 | September 1, 2022 | August 31, 2027 | YEH, JENNIFER M. | reporter.nih.gov |
| Defining the role of BARD1 in nucleosomal ubiquitylation | NIH | National Cancer Institute | 2021 to 2025 | $2,722,483 | April 1, 2021 | March 31, 2027 | KLEVIT, RACHEL E | reporter.nih.gov |
| OPTIMISE: A Shared Care Approach for Improving Comprehensive Care of Cancer Patients with Comorbidities in A Safety-Net System | NIH | National Cancer Institute | 2021 to 2025 | $2,719,421 | June 1, 2021 | June 30, 2025 | BADR, HODA J. | reporter.nih.gov |
| Copper-mediated metabolic reprogramming and ECM alterations in TNBC metastasis | NIH | National Cancer Institute | 2021 to 2025 | $2,700,030 | May 1, 2021 | April 30, 2027 | MITTAL, VIVEK | reporter.nih.gov |
| RB tumor suppressor as a therapeutic target in ER-positive breast cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,698,348 | March 1, 2020 | February 28, 2026 | KNUDSEN, ERIK | reporter.nih.gov |
| Primary Prevention to Reduce Cardiovascular Morbidity and Optimize Cancer Outcomes | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,695,216 | August 10, 2022 | June 30, 2027 | KAWATKAR, ANIKET A | reporter.nih.gov |
| Mechanisms and Impact of NRG3 Induction in Bone Metastasis | NIH | National Cancer Institute | 2025 | $2,691,173 | September 24, 2025 | August 31, 2029 | BADO, IGOR LANDRY | reporter.nih.gov |
| The interplay of ion transporters and cytoskeleton in breast cancer migration and metastasis | NIH | National Cancer Institute | 2021 to 2025 | $2,679,867 | February 2, 2021 | January 31, 2027 | KONSTANTOPOULOS, KONSTANTINOS | reporter.nih.gov |
| MYC-regulated RNA Binding Protein Networks and Spliced Isoforms Driving Cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,668,290 | February 10, 2021 | January 31, 2027 | ANCZUKOW-CAMARDA, OLGA | reporter.nih.gov |
| Pain Sensitivity and Unpleasantness in People with Alzheimer's Disease and Cancer | NIH | National Institute on Aging | 2021 to 2023 | $2,659,054 | August 15, 2019 | May 31, 2026 | COWAN, RONALD L | reporter.nih.gov |
| In vitro models as a window to learn how to change outcomes in women at high risk of developing breast cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,657,653 | September 20, 2022 | August 31, 2027 | ROSENBLUTH, JENNIFER M. | reporter.nih.gov |
| Prevention of Heart Failure induced by Doxorubicin with Early Administration of Dexrazoxane | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,654,159 | June 15, 2020 | May 31, 2025 | CHANG, HUI-MING | reporter.nih.gov |
| Interrogating the response of the tumor microenvironment to combination immunotherapy using a microfluidic platform | NIH | National Cancer Institute | 2021 to 2025 | $2,645,874 | August 5, 2014 | April 30, 2027 | FOLCH, ALBERT | reporter.nih.gov |
| Artificial Intelligence for Improved Breast Cancer Screening Accuracy: External Validation, Refinement, and Clinical Translation | NIH | National Cancer Institute | 2021 to 2025 | $2,643,927 | January 1, 2020 | December 31, 2026 | LEE, CHRISTOPH I | reporter.nih.gov |
| Development of a novel therapy targeting the tumor microenvironment in inflammatory breast cancer | NIH | National Cancer Institute | 2023 to 2025 | $2,625,297 | March 1, 2022 | August 31, 2027 | UENO, NAOTO T. | reporter.nih.gov |
| Expanding Mechanistic Insights into Protein Ubiquitylation | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $2,621,748 | August 15, 2022 | June 30, 2027 | KLEVIT, RACHEL E | reporter.nih.gov |
| Image-guided cancer therapy using heat activatable CAR T cells | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2025 | $2,619,925 | September 15, 2022 | June 30, 2027 | EMELIANOV, STANISLAV Y | reporter.nih.gov |
| The linkage between Race, Kaiso and the tumor microenvironment in breast cancer health disparities | NIH | National Cancer Institute | 2021 to 2024 | $2,609,721 | September 24, 2020 | March 12, 2025 | GARDNER, KEVIN L. | reporter.nih.gov |
| Hemopexin as an Early Biomarker of Anthracycline Cardiac Toxicity | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,606,962 | April 1, 2022 | March 31, 2027 | ASNANI, AARTI | reporter.nih.gov |
| A sequential therapeutic strategy of senescence induction and senolytics for elimination of surviving residual breast tumor cells | NIH | National Cancer Institute | 2021 to 2025 | $2,606,491 | March 1, 2021 | February 28, 2027 | GEWIRTZ, DAVID A. | reporter.nih.gov |
| Mechanistic maps of adaptive responses to therapeutic stress to optimize combination therapies. | NIH | National Cancer Institute | 2021 to 2025 | $2,603,119 | April 1, 2021 | March 31, 2026 | MILLS, GORDON B. | reporter.nih.gov |
| Improving Delivery of Genetic Services to High Risk Childhood Cancer Survivors: A Randomized Study of Remote Genetic Services Versus Usual Care | NIH | National Cancer Institute | 2021 to 2024 | $2,593,712 | July 8, 2020 | June 30, 2025 | HENDERSON, TARA OLIVE | reporter.nih.gov |
| Depleting S1P to reverse immune exclusion for effective cancer immunotherapy | NIH | National Cancer Institute | 2025 | $2,592,085 | August 1, 2025 | July 31, 2029 | STONE, EVERETT | reporter.nih.gov |
| Modulation of cancer induced immune suppression via inhibition of SCD1 | NIH | National Cancer Institute | 2022 to 2025 | $2,589,920 | September 15, 2022 | August 31, 2026 | HAYES, KAREN E | reporter.nih.gov |
| Identifying Cancer Recurrence with Novel Data Linkages with a Cancer Registry | NIH | National Cancer Institute | 2022 to 2025 | $2,585,593 | August 1, 2022 | July 31, 2027 | DOHERTY, JENNIFER ANNE | reporter.nih.gov |
| Integrating Epigenetic Modulation into DNA Damage Repair | NIH | National Cancer Institute | 2022 to 2025 | $2,584,072 | June 6, 2022 | May 31, 2027 | MUNSTER, PAMELA N. | reporter.nih.gov |
| Density MATTERS Clinical Trial | NIH | National Cancer Institute | 2021 to 2024 | $2,580,004 | September 1, 2020 | May 31, 2025 | HRUSKA, CARRIE B | reporter.nih.gov |
| Fit2ThriveMIND: Optimizing a mHealth Physical Activity Intervention with Mindful Awareness Lessons in Breast Cancer Survivors | NIH | National Cancer Institute | 2022 to 2025 | $2,578,762 | September 1, 2022 | August 31, 2027 | PHILLIPS, SIOBHAN MARIE | reporter.nih.gov |
| Dose-Dependent Effects of Hormone on the Activity of Estrogen Receptor Enhancers and Target Genes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,576,212 | September 15, 2000 | May 31, 2030 | KRAUS, WILLIAM LEE | reporter.nih.gov |
| Every Day Counts: A lifestyle program for women metastatic breast cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,571,685 | February 1, 2022 | January 31, 2027 | STOLLEY, MELINDA R | reporter.nih.gov |
| Mechanisms of replication fork protection and recovery | NIH | National Cancer Institute | 2021 to 2025 | $2,570,871 | February 12, 2020 | April 30, 2030 | VINDIGNI, ALESSANDRO | reporter.nih.gov |
| De-implementation of Mammography Overuse in Primary Care Settings | NIH | National Cancer Institute | 2021 to 2025 | $2,569,377 | February 3, 2021 | July 31, 2027 | TEHRANIFAR, PARISA | reporter.nih.gov |
| Multi-Omic Biomarkers for Neuropathic Pain Secondary to Chemotherapy | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $2,568,308 | September 30, 2020 | August 31, 2025 | ROTROFF, DANIEL | reporter.nih.gov |
| Evaluating Digital Micro-Interventions to Reduce Distress and Increase Wellbeing in Breast Cancer Survivors | NIH | National Cancer Institute | 2021 to 2025 | $2,568,159 | December 1, 2024 | November 30, 2026 | CHOW, PHILIP | reporter.nih.gov |
| Impact of brain estrogens on cognition and brain aging in a non-human primate | NIH | National Cancer Institute | 2021 to 2025 | $2,564,217 | January 1, 2021 | December 31, 2026 | LACREUSE, AGNES | reporter.nih.gov |
| Environmental Chemical Body Burden and Prospective Breast Cancer Risk in the Cancer Prevention Study-3 Cohort | NIH | National Institute of Environmental Health Sciences | 2022 to 2025 | $2,549,349 | July 20, 2022 | April 30, 2027 | NEUHAUSEN, SUSAN L. | reporter.nih.gov |
| Targeted Prevention of Postpartum-Related Breast Cancer (PRBC) | NIH | National Cancer Institute | 2022 to 2025 | $2,548,753 | February 1, 2022 | January 31, 2027 | SHERMAN, MARK E | reporter.nih.gov |
| CTL-killing capacity and cancer stiffness in cancer immunity and therapy | NIH | National Cancer Institute | 2022 to 2025 | $2,544,012 | January 7, 2022 | December 31, 2026 | ZOU, WEIPING | reporter.nih.gov |
| Delineating developmental programs driving tumorigenesis in triple-negative breast cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,543,272 | February 1, 2021 | January 31, 2027 | NEWMAN, AARON M | reporter.nih.gov |
| Molecular Mechanisms and Applications of Novel ER/GPER-selective Ligands | NIH | National Cancer Institute | 2022 to 2025 | $2,539,317 | September 7, 2016 | August 31, 2027 | PROSSNITZ, ERIC R | reporter.nih.gov |
| Phenotypic marker-guided development of selective antimetastasis therapeutic leads | NIH | National Cancer Institute | 2022 to 2025 | $2,538,566 | July 1, 2022 | June 30, 2027 | HUANG, SUI | reporter.nih.gov |
| PhytoSERM for Menopausal Hot Flashes and Sustained Brain Health | NIH | National Institute on Aging | 2022 to 2023 | $2,536,705 | September 30, 2022 | August 31, 2025 | RINEHART, JOHN | reporter.nih.gov |
| Next Generation Rat Models of ER+ Breast Cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,535,153 | March 14, 2022 | February 28, 2027 | LI, YI | reporter.nih.gov |
| HER2-targeting transformable nanotherapeutic platform against HER2+ cancers | NIH | National Cancer Institute | 2021 to 2024 | $2,533,940 | February 11, 2020 | January 31, 2026 | LAM, KIT S | reporter.nih.gov |
| Tyrosine phosphorylation of p27Kip1 as a biomarker to identify Cdk4/6 inhibitor response | NIH | National Cancer Institute | 2021 to 2025 | $2,533,106 | June 10, 2021 | November 30, 2026 | BRISSETTE, JANICE L | reporter.nih.gov |
| Health Consequences of Fear of Cancer Recurrence in Breast Cancer Survivors and Partners | NIH | National Cancer Institute | 2021 to 2025 | $2,529,473 | April 1, 2020 | March 31, 2027 | LAURENCEAU, JEAN-PHILIPPE | reporter.nih.gov |
| The impact of lifestyle and genetic factors on mammographic density in a cohort of Hispanic women | NIH | National Cancer Institute | 2022 to 2025 | $2,528,759 | February 8, 2022 | January 31, 2027 | LINDSTROEM, SARA | reporter.nih.gov |
| Web-based Pain Coping Skills Training to Improve Pain and Poor Adherence caused by Aromatase Inhibitor-Associated Arthralgia In Breast Cancer Survivors (SKIP-Arthralgia): A Randomized Controlled Trial | NIH | National Cancer Institute | 2022 to 2025 | $2,513,680 | June 1, 2022 | May 31, 2027 | RINI, CHRISTINE | reporter.nih.gov |
| Acceptance and Commitment Therapy for Fear of Recurrence in Breast Cancer Survivors | NIH | National Cancer Institute | 2021 to 2024 | $2,511,841 | July 1, 2021 | June 30, 2026 | JOHNS, SHELLEY A. | reporter.nih.gov |
| The Role of Kaiso as a predictive breast cancer biomarker in Africa and across the African Diaspora | NIH | National Cancer Institute | 2022 to 2025 | $2,504,798 | September 1, 2022 | August 31, 2027 | GARDNER, KEVIN L. | reporter.nih.gov |
| Tubulin microtentacles in detached mammary epithelial cells | NIH | National Cancer Institute | 2021 to 2025 | $2,502,441 | June 1, 2007 | August 31, 2026 | MARTIN, STUART S | reporter.nih.gov |
| Quantitative volumetric ultrasonic and photoacoustic tomography | NIH | National Cancer Institute | 2022 to 2025 | $2,502,179 | December 15, 2021 | November 30, 2026 | FERRARA, KATHERINE W | reporter.nih.gov |
| Targeting eIF4A1 in drug-resistant breast cancer stem-like cells | NIH | National Cancer Institute | 2022 to 2025 | $2,500,438 | August 9, 2022 | July 31, 2027 | RAMAN, DAYANIDHI | reporter.nih.gov |
| Proteolysis-targeting chimera against BCL-XL inhibits breast cancer metastasis | NIH | National Cancer Institute | 2021 to 2025 | $2,492,242 | May 1, 2021 | April 30, 2027 | ZHANG, WEIZHOU | reporter.nih.gov |
| Patterns of biological, cognitive, and physical aging in cancer survivors and controls and the role of sleep health: Relevance for Alzheimer's Disease and Related Dementias | NIH | National Institute on Aging | 2023 to 2025 | $2,481,590 | June 15, 2023 | February 29, 2028 | CARROLL, JUDITH E | reporter.nih.gov |
| THE EFFECT OF TUMOR MICROENVIRONMENT ON METASTASIS | NIH | National Cancer Institute | 2021 to 2025 | $2,481,158 | March 1, 2021 | February 28, 2026 | OKTAY, MAJA HRZENJAK | reporter.nih.gov |
| A Mobile Health Behavioral Pain Intervention Protocol for Breast Cancer Patients with Pain in Medically Underserved Communities: A Randomized Controlled Trial | NIH | National Cancer Institute | 2021 to 2024 | $2,478,031 | January 10, 2020 | December 31, 2025 | SOMERS, TAMARA J | reporter.nih.gov |
| Novel dietary interventions for reducing obesity-associated breast cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,477,092 | January 1, 2022 | December 31, 2026 | MACLEAN, PAUL S. | reporter.nih.gov |
| Persistent Post-Mastectomy Pain: Randomized Clinical Trial of Targeted Pain Coping Skills Training (Targeted-PCST) with Mediational Analysis | NIH | National Cancer Institute | 2021 to 2024 | $2,474,212 | April 1, 2020 | March 31, 2026 | SHELBY, REBECCA A | reporter.nih.gov |
| Enhanced Biomechanical Modeling of the Breast for Womens Health | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2025 | $2,473,996 | June 10, 2022 | February 28, 2027 | BROCK, KRISTY | reporter.nih.gov |
| TOWARD TRANSLATION OF NANFORMULATED PACLITAXEL-PLATINUM COMBINATION | NIH | National Cancer Institute | 2021 to 2024 | $2,460,645 | August 1, 2021 | July 31, 2025 | KABANOV, ALEXANDER V | reporter.nih.gov |
| Molecular Determinants of Inflammatory Breast Cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,460,561 | September 20, 2021 | August 31, 2026 | DEVI, GAYATHRI | reporter.nih.gov |
| A Conversation Aid on Mammography Screening to Support Shared Decision Making between Clinicians and Women Aged 75 and Older | NIH | National Institute on Aging | 2021 to 2024 | $2,459,754 | February 1, 2020 | November 30, 2025 | SCHONBERG, MARA A | reporter.nih.gov |
| Investigating the roles of extracellular cGAMP and harnessing it for cancer treatment | NIH | National Cancer Institute | 2021 to 2025 | $2,459,192 | April 1, 2021 | March 31, 2027 | STRAIGHT, AARON F | reporter.nih.gov |
| Energy Balance, mTOR pathway signaling, and breast cancer prognosis | NIH | National Cancer Institute | 2022 to 2025 | $2,459,133 | February 1, 2021 | January 31, 2026 | CHENG, TING-YUAN | reporter.nih.gov |
| Developing novel LOX inhibitors to target chemotherapy resistant TNBC | NIH | National Cancer Institute | 2023 to 2025 | $2,456,500 | June 8, 2023 | July 31, 2027 | SAHIN, OZGUR | reporter.nih.gov |
| Multicenter Randomized Controlled Trial of Brief Behavioral Therapy for Cancer Related Insomnia | NIH | National Cancer Institute | 2022 to 2025 | $2,452,118 | July 1, 2022 | January 31, 2027 | PALESH, OXANA G | reporter.nih.gov |
| ERβ repurposes EZH2 to suppress oncogenic NFκB signaling in TNBC | NIH | National Cancer Institute | 2021 to 2025 | $2,448,614 | January 1, 2021 | December 31, 2025 | HAWSE, JOHN R. | reporter.nih.gov |
| Developing novel bispecific antibodies for cancer treatment | NIH | National Cancer Institute | 2021 to 2025 | $2,437,200 | July 1, 2021 | June 30, 2027 | FAN, ZHEN | reporter.nih.gov |
| Modulation of the tumor microenvironment with probiotic therapies | NIH | National Cancer Institute | 2021 to 2024 | $2,436,681 | April 3, 2020 | March 31, 2026 | DANINO, TAL | reporter.nih.gov |
| Personalized Cancer Therapy Guided by Photoacoustic Chemical Imaging (PACI) of Tumor Microenvironment (TME) | NIH | National Cancer Institute | 2021 to 2025 | $2,429,748 | June 1, 2020 | May 31, 2027 | WANG, XUEDING | reporter.nih.gov |
| Nuclear Dysfunction in Cancer: The Role of Mechanical Stresses Transmittedby the LINC Complex | NIH | National Cancer Institute | 2021 to 2024 | $2,427,404 | March 6, 2020 | February 28, 2026 | LELE, TANMAY P. | reporter.nih.gov |
| Upgrading rigor and efficiency of germline cancer gene variant classification for the 2020s | NIH | National Cancer Institute | 2022 to 2025 | $2,422,203 | March 1, 2022 | January 31, 2027 | TAVTIGIAN, SEAN VAHRAM | reporter.nih.gov |
| Mechanisms of Variant ER-alpha Function in Breast Cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,417,896 | May 1, 2021 | April 30, 2027 | FOWLER, AMY | reporter.nih.gov |
| Testing scalable communication modalities for returning breast cancer genetic research results to African American women | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2024 | $2,417,666 | June 12, 2020 | November 30, 2025 | WANG, CATHARINE | reporter.nih.gov |
| Role of O-GlcNAcome on Breast Cancer Initiating Cells | NIH | National Cancer Institute | 2021 to 2024 | $2,414,370 | March 1, 2020 | February 28, 2025 | REGINATO, MAURICIO J. | reporter.nih.gov |
| Spatial single-cell profiling to identify tumor-immune-bone niche features in HER2-low bone metastasis in response to T-DXd treatment. | NIH | National Cancer Institute | 2021 to 2024 | $2,412,165 | September 15, 2020 | August 31, 2025 | WONG, STEPHEN TC | reporter.nih.gov |
| DEVELOPMENT OF AN AUTOMATED CARTRIDGE-BASED BREAST CANCER DETECTION ASSAY- AN ACADEMIC-INDUSTRIAL PARTNERSHIP | NIH | National Cancer Institute | 2022 to 2025 | $2,405,391 | July 11, 2022 | May 31, 2027 | SUKUMAR, SARASWATI | reporter.nih.gov |
| Dynamic prediction incorporating time-varying covariates for the onset of breast cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,405,186 | July 1, 2021 | June 30, 2027 | JIANG, SHU | reporter.nih.gov |
| Development of polymeric synthetic biomaterial IP-001 to potentiate asystemic immunotherapy of hepatocellular carcinoma via thermal ablation | NIH | National Cancer Institute | 2021 to 2024 | $2,400,000 | August 16, 2021 | August 31, 2025 | LAM, SIU KIT | reporter.nih.gov |
| TrAstuzumab Cardiomyopathy Therapeutic Intervention with Carvedilol (TACTIC) Trial | NIH | National Cancer Institute | 2021 to 2024 | $2,397,966 | March 1, 2019 | February 28, 2026 | HERRMANN, JOERG | reporter.nih.gov |
| Preventing adaptive drug resistance through Mediator kinase inhibition | NIH | National Cancer Institute | 2022 to 2025 | $2,396,222 | August 1, 2022 | July 31, 2027 | CHEN, MENGQIAN | reporter.nih.gov |
| TRIM37 is a genetic determinant of racial disparity in metastatic TNBC patients | NIH | National Cancer Institute | 2021 to 2025 | $2,392,951 | April 1, 2021 | March 31, 2027 | BHATNAGAR, SANCHITA | reporter.nih.gov |
| VDX-111: A novel targeted therapeutic for triple-negative breast cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,388,767 | July 1, 2021 | June 30, 2026 | LAMBERT, CHERIE | reporter.nih.gov |
| Bionic Breast Project: A Neuroprosthesis to Restore Touch Sensation and Reduce Chronic Pain After Mastectomy | NIH | National Cancer Institute | 2023 to 2025 | $2,385,909 | August 1, 2023 | July 31, 2028 | LINDAU, STACY TESSLER | reporter.nih.gov |
| Racial and Socioeconomic Disparities in Breast Cancer Diagnostic Work Up and Outcomes | NIH | National Cancer Institute | 2021 to 2024 | $2,384,069 | June 1, 2021 | May 31, 2026 | LEE, CHRISTOPH I | reporter.nih.gov |
| Immunomodulatory biomaterial to enhancing T-cell responses to triple negative breast cancer | NIH | National Cancer Institute | 2023 to 2025 | $2,380,221 | May 1, 2023 | August 31, 2026 | DASHTIMOGHADAM, ERFAN | reporter.nih.gov |
| Lung Resident Mesenchymal Cells in the Pre-Metastatic Niche Formation | NIH | National Cancer Institute | 2021 to 2025 | $2,377,950 | April 1, 2021 | March 31, 2026 | REN, GUANGWEN | reporter.nih.gov |
| Using a SMART design to evaluate remotely delivered, community-aligned weight loss interventions among breast cancer survivors | NIH | National Cancer Institute | 2023 to 2025 | $2,377,399 | July 1, 2023 | June 30, 2028 | GREENLEE, HEATHER | reporter.nih.gov |
| Adapting and implementing evidence-based breast cancer follow-up in primary care | NIH | National Cancer Institute | 2023 to 2025 | $2,376,183 | July 1, 2021 | June 30, 2027 | HUDSON, SHAWNA V. | reporter.nih.gov |
| Reposition and Optimization of Deferiprone for Breast Cancer Therapy | NIH | National Cancer Institute | 2021 to 2025 | $2,369,493 | March 1, 2021 | February 28, 2027 | OYELERE, ADEGBOYEGA | reporter.nih.gov |
| An integrated polymeric carrier for subunit cancer vaccines | NIH | National Cancer Institute | 2021 to 2025 | $2,360,660 | March 5, 2021 | February 28, 2027 | PUN, SUZIE H. | reporter.nih.gov |
| In vivo Evaluation of Lymph Nodes Using Quantitative Ultrasound | NIH | National Cancer Institute | 2023 to 2025 | $2,359,210 | August 2, 2023 | July 31, 2028 | MAMOU, JONATHAN | reporter.nih.gov |
| Clinical breast cancer risk prediction models for women with a high-risk benign breast diagnosis | NIH | National Cancer Institute | 2023 to 2025 | $2,356,042 | September 19, 2023 | August 31, 2028 | SPRAGUE, BRIAN L | reporter.nih.gov |
| Point-of-care cellular and molecular pathology of breast tumors on a cell phone | NIH | National Cancer Institute | 2021 to 2024 | $2,355,589 | March 1, 2020 | February 28, 2026 | CHILKOTI, ASHUTOSH | reporter.nih.gov |
| Mechanisms of progression of vascular malformation to lymphangiosarcoma | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,351,725 | April 8, 2003 | June 30, 2027 | GUAN, JUN-LIN | reporter.nih.gov |
| Elucidating SAMHD1 in DNA Double-Strand Break Repair | NIH | National Cancer Institute | 2021 to 2024 | $2,348,978 | July 11, 2020 | June 30, 2026 | YU, DAVID SUNG-WEN | reporter.nih.gov |
| Progesterone Receptor (PR) Signaling Cross Talk Drives ER+ Breast Cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,348,652 | February 13, 2020 | July 31, 2025 | LANGE, CAROL A | reporter.nih.gov |
| Visualizing tumor heterogeneity in an immune intact and autochthonous mouse model of breast cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,342,501 | February 9, 2021 | January 31, 2026 | SNYDER, JOSHUA CLAIR | reporter.nih.gov |
| Understanding breast cancer progression as a defect in the mechanics of tissue self-organization | NIH | National Cancer Institute | 2021 to 2024 | $2,342,075 | May 1, 2020 | April 30, 2025 | GARTNER, ZEV JORDAN | reporter.nih.gov |
| Tunneling Nanotube Inhibitors for Cancer Immunotherapy | NIH | National Cancer Institute | 2023 to 2025 | $2,339,448 | July 19, 2023 | June 30, 2028 | SENGUPTA, SHILADITYA | reporter.nih.gov |
| A tissue viability imaging biomarker for use in non-invasive breast cancer therapy | NIH | National Cancer Institute | 2022 to 2025 | $2,335,729 | February 10, 2022 | January 31, 2027 | PAYNE, ALLISON | reporter.nih.gov |
| Simultaneous Microwave and MR Imaging for Improved Diagnosis of Breast Abnormalities | NIH | National Cancer Institute | 2021 to 2024 | $2,335,554 | February 15, 2020 | February 28, 2026 | PAULSEN, KEITH D. | reporter.nih.gov |
| The non-catalytic function of PARP2 in DNA repair and cancer therapy | NIH | National Cancer Institute | 2022 to 2025 | $2,334,267 | July 1, 2022 | June 30, 2027 | ZHA, SHAN | reporter.nih.gov |
| Mobile Device CBT for Chemotherapy-Related Cognitive Dysfunction: A Multi-Center Randomized Controlled Trial | NIH | National Cancer Institute | 2021 to 2024 | $2,330,454 | June 1, 2020 | May 31, 2026 | POSLUSZNY, DONNA M | reporter.nih.gov |
| Viscotaxis: Novel cell migration mechanisms regulated by microenvironmental viscosity | NIH | National Cancer Institute | 2021 to 2025 | $2,329,274 | April 1, 2021 | March 31, 2027 | KONSTANTOPOULOS, KONSTANTINOS | reporter.nih.gov |
| Development of CapCell Scope for Metabolic Imaging of Tissue Heterogeneity and Therapy Response | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2025 | $2,329,025 | July 18, 2024 | April 30, 2028 | RAMANUJAM, NIRMALA | reporter.nih.gov |
| Messaging Strategies to Reduce Breast Cancer Over-Screening in Older Women | NIH | National Institute on Aging | 2021 to 2024 | $2,326,561 | April 15, 2021 | March 31, 2026 | SCHOENBORN, NANCY | reporter.nih.gov |
| Axonal transport and chemotherapy induced peripheral neuropathy | NIH | National Cancer Institute | 2022 to 2025 | $2,319,802 | April 1, 2016 | June 30, 2027 | SEGAL, ROSALIND A. | reporter.nih.gov |
| EPHA2 Receptor Signaling in Breast Cancer Mechanotransduction | NIH | National Cancer Institute | 2022 to 2025 | $2,315,344 | June 1, 2022 | May 31, 2027 | PASQUALE, ELENA B | reporter.nih.gov |
| Improving treatment of HER2+ breast cancer brain metastasis by targeting lipid metabolism | NIH | National Cancer Institute | 2021 to 2025 | $2,312,485 | May 1, 2021 | April 30, 2026 | JAIN, RAKESH K. | reporter.nih.gov |
| Image-Guided Intraductal Ablative Procedure for Primary Prevention of Breast Cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,311,011 | December 14, 2021 | November 30, 2026 | SEMPERE, LORENZO | reporter.nih.gov |
| Targeted immuno-nanoparticles for directing antitumor immune response against breast cancer metastasis | NIH | National Cancer Institute | 2021 to 2024 | $2,308,906 | August 1, 2020 | April 30, 2025 | KARATHANASIS, EFSTATHIOS | reporter.nih.gov |
| Clinical Development of First-in-Class Therapy for Metastatic Breast Cancer | NIH | National Cancer Institute | 2021 to 2023 | $2,308,861 | April 15, 2021 | March 31, 2024 | MEDAROVA, ZDRAVKA O | reporter.nih.gov |
| Improving access to multidisciplinary cancer care and patient outcomes by targeting physician networks | NIH | National Cancer Institute | 2021 to 2025 | $2,308,736 | July 1, 2025 | June 30, 2027 | MOEN, ERIKA | reporter.nih.gov |
| A Computational Framework Enabling Virtual Imaging Trials of 3D Quantitative Optoacoustic Tomography Breast Imaging | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2025 | $2,308,021 | August 1, 2022 | April 30, 2027 | ANASTASIO, MARK A | reporter.nih.gov |
| Longitudinal investigation of sociocultural and behavioral influences on symptom management, biological response, and functioning between Chinese and White breast cancer survivors. | NIH | National Cancer Institute | 2021 to 2025 | $2,299,463 | March 1, 2021 | February 28, 2027 | WANG, JUDY HUEI-YU | reporter.nih.gov |
| Exosome secretion in breast cancer progression | NIH | National Cancer Institute | 2021 to 2025 | $2,289,245 | April 15, 2016 | March 31, 2027 | WEAVER, ALISSA M | reporter.nih.gov |
| The Breast Cancer and the Workforce Communication App: A randomized controlled trial of an English/Spanish intervention to promote long-term job retention | NIH | National Cancer Institute | 2021 to 2024 | $2,287,303 | February 1, 2023 | January 31, 2026 | BLINDER, VICTORIA S | reporter.nih.gov |
| Tuning PARP-1 retention and release on DNA breaks | NIH | National Cancer Institute | 2022 to 2025 | $2,281,849 | March 1, 2022 | February 28, 2027 | BLACK, BEN E. | reporter.nih.gov |
| Targeting vulnerabilities in copper metabolism in the development of cancer therapies | NIH | National Cancer Institute | 2021 to 2025 | $2,281,479 | August 3, 2021 | July 31, 2027 | PETRIS, MICHAEL J. | reporter.nih.gov |
| Combined Methylation and Mutation to Predict Response to PARP Inhibitors | NIH | National Cancer Institute | 2021 to 2024 | $2,278,082 | April 1, 2020 | March 31, 2025 | SWISHER, ELIZABETH MARY | reporter.nih.gov |
| Targeting MUC5AC mucin in breast cancer brain metastasis | NIH | National Cancer Institute | 2021 to 2025 | $2,276,402 | February 1, 2021 | January 31, 2027 | NASSER, MOHD WASIM | reporter.nih.gov |
| MRI Radiomic Signatures of DCIS to Optimize Treatment | NIH | National Cancer Institute | 2022 to 2025 | $2,271,876 | July 1, 2022 | June 30, 2027 | RAHBAR, HABIBOLLAH | reporter.nih.gov |
| Combine mitochondrial gene therapy and synthetic lethal chemotherapy to treat triple-negative breast cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,266,573 | June 10, 2022 | May 31, 2027 | LIU, XIAOGUANG MARGARET | reporter.nih.gov |
| A platform to functionally sort and analyze tumor cells within combinatorial metastatic micorenvironments | NIH | National Cancer Institute | 2021 to 2024 | $2,264,251 | May 8, 2020 | April 30, 2025 | WOOD, DAVID KEVIN | reporter.nih.gov |
| Mechanisms of mitotic regulation | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $2,260,225 | January 1, 2023 | November 30, 2027 | STUKENBERG, P. TODD | reporter.nih.gov |
| SELENOF is a Novel Tumor Suppressor and a New Target to Overcome Health Disparity in Breast Cancer | NIH | National Cancer Institute | 2023 to 2025 | $2,252,222 | September 11, 2023 | August 31, 2028 | KASTRATI, IRIDA | reporter.nih.gov |
| Improving Perception in Digital Breast Tomography | NIH | National Cancer Institute | 2022 to 2025 | $2,250,365 | September 14, 2016 | August 31, 2027 | WOLFE, JEREMY M | reporter.nih.gov |
| Elution of a Small Molecule from a Bio Ceramic Collagen Bone Graft Device Heals Bone while InhibitingBreast Cancer Bone Metastases | NIH | National Cancer Institute | 2021 to 2022 | $2,249,777 | November 30, 2021 | August 31, 2022 | MARGULIES, BRYAN SAMUEL | reporter.nih.gov |
| Function and Mechanism of the Hippo-PI5P4K Axis for Growth Control | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $2,247,650 | July 1, 2022 | June 30, 2026 | EMERLING, BROOKE M. | reporter.nih.gov |
| Relaxed Polymerase Pausing as a Driver of Epigenetic Plasticity and Cancer Cell Invasion | NIH | National Cancer Institute | 2021 to 2025 | $2,246,741 | April 1, 2021 | March 31, 2027 | VERTINO, PAULA M. | reporter.nih.gov |
| Involution-based biomarkers of breast cancer risk | NIH | National Cancer Institute | 2021 to 2024 | $2,246,190 | September 1, 2020 | May 31, 2025 | RADISKY, DEREK C | reporter.nih.gov |
| Engineering In Vivo Chimeric Antigen Receptor Macrophages (CARMs) using mRNA-exosomes for Cancer Immunotherapy | NIH | National Cancer Institute | 2023 to 2025 | $2,242,875 | August 1, 2023 | July 31, 2027 | JIANG, WEN | reporter.nih.gov |
| In vivo Macroscopic Fluorescence Lifetime Molecular Optical Imaging | NIH | National Cancer Institute | 2021 to 2023 | $2,239,459 | May 1, 2020 | April 30, 2025 | INTES, XAVIER | reporter.nih.gov |
| Biomaterials for Targeted Modulation of Conventional Type 1 Dendritic Cells | NIH | National Cancer Institute | 2022 to 2025 | $2,229,562 | September 5, 2022 | August 31, 2027 | WANG, HUA | reporter.nih.gov |
| Targeting Effector Immune cells to Cancer with Chemically Self-Assembled Nanorings (CSANs) | NIH | National Cancer Institute | 2021 to 2024 | $2,229,339 | March 1, 2020 | June 30, 2025 | WAGNER, CARSTON R. | reporter.nih.gov |
| Real-time volumetric specimen imager for 3D intra-operative lumpectomy margin assessment | NIH | National Cancer Institute | 2021 to 2022 | $2,226,705 | September 1, 2016 | May 31, 2024 | HAN, XIAO | reporter.nih.gov |
| Endosome-mitochondria interactions in breast cancer cells | NIH | National Cancer Institute | 2021 to 2024 | $2,225,078 | February 1, 2020 | January 31, 2026 | BARROSO, MARGARIDA | reporter.nih.gov |
| CDK4/6 inhibition during CD8 T cell priming potentiates memory formation in mice and humans | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,225,000 | April 5, 2021 | March 31, 2027 | DOUGAN, STEPHANIE | reporter.nih.gov |
| A Platform Technology to Genetically Reprogram Cancer Cells for Enhanced Immunotherapy | NIH | National Cancer Institute | 2021 to 2025 | $2,221,249 | July 1, 2025 | June 30, 2027 | TZENG, STEPHANY YI | reporter.nih.gov |
| Effects of chronic pubertal stressors on mammary gland biology and cancer risk | NIH | National Cancer Institute | 2021 to 2025 | $2,220,324 | July 1, 2020 | June 30, 2027 | BRADY, MATTHEW J | reporter.nih.gov |
| Fluorescence-guided resection of breast tumors using a topically-applied molecular probe | NIH | National Cancer Institute | 2021 to 2025 | $2,216,073 | January 1, 2020 | August 31, 2026 | BASILION, JAMES PETER | reporter.nih.gov |
| Computational and experimental methods for scalable identification of oncogenic non-coding regions | NIH | National Cancer Institute | 2021 to 2025 | $2,213,425 | July 1, 2018 | March 31, 2029 | KHURANA, EKTA | reporter.nih.gov |
| Multiscale analysis of metabolic inflammation as a driver of breast cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,213,238 | September 9, 2020 | August 31, 2025 | DENIS, GERALD V | reporter.nih.gov |
| Delineating Functional Immunity via Image-Guided PET | NIH | National Cancer Institute | 2021 to 2024 | $2,209,344 | August 1, 2023 | July 31, 2025 | VIOLA, NERISSA THERESE | reporter.nih.gov |
| Pentraxin-3 in the Pathogenesis and Management of Triple-Negative Breast Cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,201,577 | July 1, 2021 | June 30, 2026 | KARNOUB, ANTOINE ELIAS | reporter.nih.gov |
| Monitoring neoadjuvant chemotherapy of breast cancer using 3D subharmonic aided pressure estimation | NIH | National Cancer Institute | 2021 to 2025 | $2,200,983 | July 1, 2019 | May 31, 2026 | NAM, KIBO | reporter.nih.gov |
| Synergistic combinatorial DNA damage response/repair inhibition and Sacituzumab Govitecan in triple-negative breast cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,199,947 | January 1, 2022 | December 31, 2026 | ELLISEN, LEIF W | reporter.nih.gov |
| Obesity, chemotherapy dosing, and breast cancer outcomes | NIH | National Cancer Institute | 2021 to 2024 | $2,193,060 | January 1, 2018 | December 31, 2024 | KANTOR, ELIZABETH DAVID | reporter.nih.gov |
| Mapping & quantifying lymphatic drainage of the arm's alternate pathway | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,188,750 | January 26, 2021 | December 31, 2026 | SINGHAL, DHRUV | reporter.nih.gov |
| MiR-152/PKM2/SLC7A5 axis in breast cancer development, chemo- and radiation-treatment response | NIH | National Cancer Institute | 2022 to 2025 | $2,185,830 | April 1, 2022 | March 31, 2027 | HE, JUN | reporter.nih.gov |
| Multifrequency ultrasound imaging for improved breast tissue characterization | NIH | National Cancer Institute | 2023 to 2025 | $2,181,031 | August 1, 2025 | July 31, 2027 | HOYT, KENNETH | reporter.nih.gov |
| Privacy-Aware Federated Learning for Breast Cancer Risk Assessment | NIH | National Cancer Institute | 2023 to 2025 | $2,177,242 | September 20, 2023 | August 31, 2028 | BAKAS, SPYRIDON | reporter.nih.gov |
| Diversity in the Cancer Care Workforce | NIH | National Institute on Minority Health and Health Disparities | 2023 to 2025 | $2,175,699 | June 23, 2023 | December 31, 2025 | GROSS, CARY P. | reporter.nih.gov |
| PMCA2 regulates mammary gland involution and breast cancer | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $2,173,478 | April 10, 2014 | June 30, 2025 | WYSOLMERSKI, JOHN J | reporter.nih.gov |
| Optimizing prognostic and predictive algorithms using residual disease (RD) genomic biomarkers in HER2+ and TNBC | NIH | National Cancer Institute | 2021 to 2025 | $2,170,498 | June 1, 2019 | May 31, 2030 | CAREY, LISA A | reporter.nih.gov |
| Mechanisms of racial disparity in breast cancer-related lymphedema | NIH | National Cancer Institute | 2023 to 2025 | $2,166,923 | January 1, 2023 | December 31, 2027 | MEHRARA, BABAK J | reporter.nih.gov |
| Microenvironmental regulation of breast tumorigenesis | NIH | National Cancer Institute | 2021 to 2025 | $2,166,708 | February 1, 2019 | July 31, 2029 | KESSENBROCK, KAI | reporter.nih.gov |
| Targeting STAT3 for the Treatment of CDK4/6 Inhibitor Resistant Advanced Estrogen Receptor Positive Breast Cancer Patients | NIH | National Cancer Institute | 2021 to 2025 | $2,161,269 | December 9, 2020 | November 30, 2026 | KEYOMARSI, KHANDAN | reporter.nih.gov |
| Cognitive Aging, Alzheimers disease, and Cancer-related Cognitive Decline | NIH | National Institute on Aging | 2021 to 2023 | $2,160,777 | August 1, 2020 | April 30, 2025 | MANDELBLATT, JEANNE | reporter.nih.gov |
| Therapeutic Targeting of Casein Kinase-1-delta in Primary and Metastatic Breast Cancer | NIH | National Cancer Institute | 2021 to 2023 | $2,159,273 | June 4, 2018 | November 30, 2023 | DUCKETT, DEREK RONALD | reporter.nih.gov |
| Cognitive aging in long-term breast cancer survivors | NIH | National Cancer Institute | 2023 to 2025 | $2,158,187 | September 1, 2023 | August 31, 2028 | ROOT, JAMES C | reporter.nih.gov |
| The role of TRIM37 in driving tumorigenesis and cancer-specific vulnerability to PLK4 inhibition | NIH | National Cancer Institute | 2022 to 2025 | $2,153,405 | June 1, 2022 | May 31, 2027 | REGOT, SERGI | reporter.nih.gov |
| BRCA1 and the regulation of chromatin dynamics in gene expression | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,150,874 | September 1, 2016 | May 31, 2026 | LONG, DAVID THOMAS | reporter.nih.gov |
| Loss of NF1 drives hormone dependent mammary carcinogenesis in a rat model with intact immune system | NIH | National Cancer Institute | 2022 to 2025 | $2,150,431 | July 1, 2022 | June 30, 2027 | WALLIS-SCHULTZ, DEEANN | reporter.nih.gov |
| Development of Long non-coding RNA-directed Target Therapy for Triple-Negative Breast Cancer | NIH | National Cancer Institute | 2021 to 2023 | $2,146,722 | March 1, 2019 | August 31, 2025 | LIN, CHUNRU | reporter.nih.gov |
| Detection of Emergent Mechanical Properties of Biologically Complex Cellular States | NIH | National Institute of Biomedical Imaging and Bioengineering | 2023 to 2025 | $2,144,508 | August 1, 2017 | February 28, 2027 | SOHN, LYDIA L | reporter.nih.gov |
| Hawaii Pacific Islands Mammography Registry | NIH | National Cancer Institute | 2023 to 2025 | $2,141,805 | March 8, 2023 | February 29, 2028 | SHEPHERD, JOHN ALAN | reporter.nih.gov |
| Novel Strategy of PDE5-mTOR Inhibition in Attenuation of Cancer Drug Cardiotoxicity | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,141,452 | July 1, 2022 | June 30, 2027 | DAS, ANINDITA | reporter.nih.gov |
| Targeting TREM2 to boost anti-cancer therapy | NIH | National Cancer Institute | 2021 to 2025 | $2,140,891 | September 1, 2021 | August 31, 2026 | COLONNA, MARCO | reporter.nih.gov |
| Spatiotemporal tools to interrogate O-GlcNAc functions in cellular signaling | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,139,830 | July 1, 2021 | July 31, 2026 | FEHL, CHARLIE | reporter.nih.gov |
| Delineating the dystopian nature of the cell cycle in cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,136,375 | June 3, 2022 | May 31, 2027 | KNUDSEN, ERIK | reporter.nih.gov |
| Dissecting the impact of tumor-intrinsic chromosomal instability on the cancer ecosystem | NIH | National Cancer Institute | 2023 to 2025 | $2,134,870 | June 8, 2023 | May 31, 2028 | LAUGHNEY, ASHLEY MARIE | reporter.nih.gov |
| Developing a personalized breast cancer screening tool using sequential mammograms | NIH | National Cancer Institute | 2021 to 2025 | $2,134,327 | June 1, 2025 | May 31, 2027 | LEE, JUHUN | reporter.nih.gov |
| Regulation of Tumor Invasion and Metastasis by Matrix Stiffness | NIH | National Cancer Institute | 2022 to 2025 | $2,124,272 | August 1, 2015 | January 31, 2027 | YANG, JING | reporter.nih.gov |
| Role of microbially-derived metabolites in anti-tumor immunity in breast cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,124,146 | August 1, 2020 | August 31, 2030 | MAKOWSKI-HAYES, LIZA | reporter.nih.gov |
| Mitophagy-Mediated Cell Death in Mammary Tumorigenesis | NIH | National Cancer Institute | 2021 to 2025 | $2,120,635 | September 1, 2021 | August 31, 2026 | SCHAFER, ZACHARY T. | reporter.nih.gov |
| Validation and translation of a non-invasive, MR-guided breast cancer therapy | NIH | National Cancer Institute | 2021 to 2024 | $2,115,474 | February 1, 2023 | January 31, 2026 | PAYNE, ALLISON | reporter.nih.gov |
| Leader cell development and function in Breast Tumor Collective Migration | NIH | National Cancer Institute | 2022 to 2025 | $2,114,516 | May 5, 2022 | March 31, 2027 | LONGMORE, GREGORY D. | reporter.nih.gov |
| Development of New Casein Kinase 1 Inhibitor for the Treatment of Brain Cancers | NIH | National Cancer Institute | 2021 to 2023 | $2,114,438 | May 15, 2018 | November 30, 2024 | DUCKETT, DEREK RONALD | reporter.nih.gov |
| Targeting 6-Phosphofructo-2-Kinase to increase efficacy of CDK4/6 Inhibitors | NIH | National Cancer Institute | 2021 to 2025 | $2,113,428 | July 1, 2025 | June 30, 2027 | IMBERT-FERNANDEZ, YOANNIS | reporter.nih.gov |
| Modulation of Epigenetic Target in the Bone to Treat Breast Cancer Metastasis | NIH | National Cancer Institute | 2021 to 2024 | $2,113,246 | July 1, 2020 | June 30, 2025 | ZHANG, XIANG | reporter.nih.gov |
| Dynamic imaging and tissue biomarker models to delineate indolent from aggressive breast calcifications | NIH | National Cancer Institute | 2022 to 2025 | $2,110,860 | September 15, 2022 | August 31, 2027 | GRIMM, LARS J | reporter.nih.gov |
| Exercise as Interception Therapy in Primary High Risk Cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,107,239 | September 3, 2020 | June 30, 2026 | JONES, LEE W | reporter.nih.gov |
| Stromal contributions to breast carcinogenesis | NIH | National Cancer Institute | 2023 to 2025 | $2,104,868 | July 3, 2023 | June 30, 2028 | YAGHJYAN, LUSINE | reporter.nih.gov |
| MnSOD-K68-Ac reprograms a lineage plasticity switch / stemness in ER+ breast malignancies | NIH | National Cancer Institute | 2021 to 2025 | $2,103,010 | January 9, 2021 | December 31, 2026 | GIUS, DAVID | reporter.nih.gov |
| PET Imaging of Glutamine Metabolism and Glutamate Transport to Guide Metabolically Targeted Therapy in Triple-Negative Breast Cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,099,338 | May 19, 2022 | April 30, 2027 | MANKOFF, DAVID A. | reporter.nih.gov |
| Endothelial Cell-Targeted Amatoxin Conjugates for Effective Therapy of Breast Cancer | NIH | National Cancer Institute | 2021 to 2023 | $2,098,231 | July 1, 2019 | December 31, 2024 | OLENYUK, BOGDAN | reporter.nih.gov |
| A value affirmation intervention for physical symptoms and medication adherence in breast cancer patients taking aromatase inhibitors | NIH | National Cancer Institute | 2021 to 2025 | $2,097,989 | December 1, 2019 | November 30, 2025 | CRESWELL, JOHN DAVID | reporter.nih.gov |
| Mitophagy Dependent Regulation of Mammary Gland Differentiation | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $2,094,708 | September 1, 2021 | July 31, 2027 | PORTER, WESTON W | reporter.nih.gov |
| Clinical Evaluation of a Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitors for Triple Negative Breast Cancer | NIH | National Cancer Institute | 2021 to 2022 | $2,094,022 | September 16, 2021 | August 31, 2024 | PACK, CHRISTOPHER D | reporter.nih.gov |
| Mitochondrial lateral transfer during metastasis | NIH | National Cancer Institute | 2021 to 2025 | $2,081,728 | February 1, 2021 | January 31, 2026 | ROH, MINNA | reporter.nih.gov |
| Improving PRO Interpretation at the Individual Level for Patients with Cancer using Conversational Agents and Data Visualization | NIH | National Cancer Institute | 2023 to 2025 | $2,081,716 | March 1, 2022 | February 28, 2027 | PAASCHE-ORLOW, MICHAEL | reporter.nih.gov |
| An AI-enabled Digital Pathology Platform for Multi-Cancer Diagnosis, Prognosis and Prediction of Therapeutic Benefit | NIH | National Cancer Institute | 2022 to 2025 | $2,081,138 | September 5, 2022 | August 31, 2027 | MADABHUSHI, ANANT | reporter.nih.gov |
| Developing a quantitative ultrasound breast scanner for identifying early response of breast cancer to chemotherapy | NIH | National Cancer Institute | 2022 to 2025 | $2,073,997 | August 18, 2022 | July 31, 2027 | OELZE, MICHAEL L. | reporter.nih.gov |
| Transcriptional regulation of mammary gland development | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2025 | $2,073,142 | July 1, 2022 | March 31, 2027 | ANDRECHEK, ERAN ROBERT | reporter.nih.gov |
| Quantitative histopathology for cancer prognosis using quantitative phase imaging on stained tissues | NIH | National Cancer Institute | 2021 to 2023 | $2,070,863 | July 12, 2019 | June 30, 2025 | ANASTASIO, MARK A | reporter.nih.gov |
| Mre11-Dependent DNA Damage Responses in Breast Cancer Pathogenesis | NIH | National Cancer Institute | 2021 to 2025 | $2,067,982 | December 1, 2018 | November 30, 2026 | GUPTA, GAORAV P. | reporter.nih.gov |
| Exploring the Function of MHC-II/Lag3 Axis in Brain Metastasis to Develop Novel Therapeutic Strategies | NIH | National Cancer Institute | 2022 to 2025 | $2,067,707 | July 5, 2022 | June 30, 2027 | YU, DIHUA | reporter.nih.gov |
| Multinuclear MRI to Monitor Breast Cancer Therapy | NIH | National Cancer Institute | 2023 to 2025 | $2,065,503 | December 1, 2022 | November 30, 2027 | MADELIN, GUILLAUME | reporter.nih.gov |
| Collagen Sequence Variants in Racial Disparities of Breast Cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,062,053 | July 3, 2020 | June 30, 2025 | ANGEL, PEGGI M | reporter.nih.gov |
| Targeting tumor-associated macrophages for triple-negative breast cancer treatment | NIH | National Cancer Institute | 2022 to 2025 | $2,060,620 | December 1, 2021 | November 30, 2026 | FENG, MINGYE | reporter.nih.gov |
| Infertility History and Chronic Disease Profile | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2023 | $2,056,267 | May 15, 2019 | April 30, 2025 | RISINGER, JOHN IAN | reporter.nih.gov |
| Harmonization of breast MRI data | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2025 | $2,055,065 | September 15, 2022 | June 30, 2027 | MAZUROWSKI, MACIEJ A. | reporter.nih.gov |
| An Electronic Health Record-Based Tool to Identify Newly Diagnosed Breast Cancer Patients at Risk of Low Social Support | NIH | National Cancer Institute | 2021 to 2025 | $2,054,601 | September 1, 2020 | May 31, 2027 | KROENKE, CANDYCE H | reporter.nih.gov |
| Targeting cell cycle and metabolic pathways of high risk breast cancers using mouse models of hyperinsulinemia | NIH | National Cancer Institute | 2021 to 2024 | $2,053,596 | July 1, 2020 | June 30, 2025 | REDDY, E PREMKUMAR | reporter.nih.gov |
| Improving medication adherence using a CONnected CUstomized Treatment Platform (CONCURxP) | NIH | National Cancer Institute | 2022 to 2025 | $2,046,913 | August 10, 2022 | July 31, 2028 | SADIGH, GELAREH | reporter.nih.gov |
| Upright, Low-dose, High-resolution, 3D Breast CT | NIH | National Cancer Institute | 2021 to 2023 | $2,046,582 | June 1, 2019 | May 31, 2025 | VEDANTHAM, SRINIVASAN | reporter.nih.gov |
| Platform to support clinical variant interpretation through probabilistic assessment of functional evidence | NIH | National Human Genome Research Institute | 2024 to 2025 | $2,046,556 | January 23, 2023 | May 31, 2027 | SCHAFER, NICHOLAS P | reporter.nih.gov |
| Development of CA-IL-12 for Triple Negative Breast Cancer | NIH | National Cancer Institute | 2023 to 2024 | $2,042,215 | September 1, 2023 | August 31, 2025 | FILARDO, EDWARD J | reporter.nih.gov |
| QBS10072S for the Treatment of Brain Metastatic Triple-Negative Breast Cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,042,076 | September 1, 2021 | May 31, 2025 | RINGOLD, GORDON M | reporter.nih.gov |
| Smart nanoparticles regulating oncogenic IncRNA for breast cancer therapy | NIH | National Cancer Institute | 2021 to 2025 | $2,041,762 | December 12, 2018 | November 30, 2028 | LU, ZHENG-RONG | reporter.nih.gov |
| Radiomic and genomic predictors of breast cancer risk | NIH | National Cancer Institute | 2022 to 2025 | $2,041,484 | September 13, 2021 | November 30, 2026 | SIEH, WEIVA | reporter.nih.gov |
| Cancer patient on a chip | NIH | National Cancer Institute | 2021 to 2024 | $2,041,238 | July 15, 2020 | June 30, 2025 | VUNJAK-NOVAKOVIC, GORDANA | reporter.nih.gov |
| The Role of 27-hydroxycholesterol in Breast Cancer: A Population-Based Multiethnic Study | NIH | National Cancer Institute | 2021 to 2023 | $2,039,519 | March 1, 2019 | February 28, 2025 | LOO, LENORA WM | reporter.nih.gov |
| High Performance, Quantitative Breast PET Scanner Integrated With Tomosynthesis | NIH | National Cancer Institute | 2023 to 2025 | $2,038,588 | April 1, 2016 | November 30, 2027 | SURTI, SULEMAN | reporter.nih.gov |
| Therapeutic Targeting of Breast Cancer Tumor Initiating Cells | NIH | National Cancer Institute | 2021 to 2025 | $2,037,554 | March 17, 2010 | March 31, 2026 | PEROU, CHARLES M | reporter.nih.gov |
| Discrete Frequency Infrared Spectroscopic Imaging for Breast Histopathology | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2025 | $2,035,199 | May 1, 2010 | November 30, 2026 | BHARGAVA, ROHIT | reporter.nih.gov |
| Understanding how elevated triglycerides contribute to triple negative breast cancer growth and metastasis | NIH | National Cancer Institute | 2022 to 2025 | $2,033,043 | August 1, 2022 | July 31, 2027 | GALLAGHER, EMILY JANE | reporter.nih.gov |
| Vitamin K: Body Pools and Function in Breast Cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,031,128 | February 9, 2021 | January 31, 2027 | WELSH, JOELLEN | reporter.nih.gov |
| Circadian Regulation of Cellular Homeostasis | NIH | National Institute of Environmental Health Sciences | 2022 to 2025 | $2,027,951 | March 18, 2022 | December 31, 2026 | PORTER, WESTON W | reporter.nih.gov |
| Targeting Oncostatin M-Receptor to Suppress Metastasis and Therapy Failure | NIH | National Cancer Institute | 2021 to 2025 | $2,026,897 | March 4, 2021 | February 28, 2026 | JACKSON, MARK W. | reporter.nih.gov |
| Targeting Senescence to Mitigate Chemotherapy-induced Functional Decline | NIH | National Cancer Institute | 2023 to 2025 | $2,026,604 | September 1, 2023 | August 31, 2028 | SEDRAK, MINA S | reporter.nih.gov |
| Neutrophil Extracellular Traps and Host Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,025,000 | March 4, 2021 | February 28, 2027 | SHARMA, JYOTIKA | reporter.nih.gov |
| Regulation of Tumor Oxygenation by BACH1 in Breast Cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,019,611 | September 1, 2022 | August 31, 2027 | ROSNER, MARSHA R | reporter.nih.gov |
| Advancing breast cancer risk prediction in national cohorts: the role of mammogram-based deep learning | NIH | National Cancer Institute | 2023 to 2025 | $2,016,928 | September 21, 2023 | August 31, 2027 | TEHRANIFAR, PARISA | reporter.nih.gov |
| Probiotic guided CAR-T therapy (ProCARs) for breast cancer | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2023 | $2,016,458 | September 15, 2020 | May 31, 2024 | DANINO, TAL | reporter.nih.gov |
| Role of ACER2 in cancer chemoresistance and metastasis | NIH | National Cancer Institute | 2022 to 2025 | $2,015,266 | July 1, 2022 | June 30, 2027 | MAO, CUNGUI | reporter.nih.gov |
| Role of necrosis in the evolution of highly metastatic and chemo-resistant breast cancers | NIH | National Cancer Institute | 2023 to 2025 | $2,015,238 | August 23, 2023 | July 31, 2028 | CHEUNG, KEVIN JON | reporter.nih.gov |
| Translational Neuroscience Approaches to Cancer-Related Cognitive Impairment: Measurement, Mechanisms, and Function | NIH | National Cancer Institute | 2021 to 2024 | $2,014,681 | July 1, 2019 | June 30, 2026 | JANELSINS, MICHELLE C | reporter.nih.gov |
| DAP5-dependent translational control and breast cancer metastasis | NIH | National Cancer Institute | 2021 to 2024 | $2,014,165 | March 2, 2020 | February 28, 2026 | SCHNEIDER, ROBERT JAY | reporter.nih.gov |
| Role of Transcription Factor ADP-ribosylation in Breast Cancer Biology | NIH | National Cancer Institute | 2021 to 2025 | $2,012,494 | April 1, 2021 | March 31, 2026 | KRAUS, WILLIAM LEE | reporter.nih.gov |
| Evaluation of novel tomosynthesis density measures in breast cancer risk prediction | NIH | National Cancer Institute | 2023 to 2025 | $2,010,802 | March 1, 2023 | February 28, 2028 | VACHON, CELINE M | reporter.nih.gov |
| Addressing the Biology of Health Disparities by Targeting Geographical Ancestry-driven Variants of Immunity | NIH | National Institute on Minority Health and Health Disparities | 2023 to 2025 | $2,010,639 | September 20, 2021 | May 31, 2027 | KIMBRO, KEVIN SEAN | reporter.nih.gov |
| Optimizing Therapeutic STING Agonism in Triple Negative Breast Cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,007,374 | April 1, 2021 | March 31, 2027 | BARBIE, THANH UYEN | reporter.nih.gov |
| MammoCAT Advanced Full Field Digital Mammography System | NIH | National Cancer Institute | 2022 to 2023 | $2,002,658 | March 1, 2022 | February 28, 2026 | BAMBOT, SHABBIR BAKIR | reporter.nih.gov |
| The Effects of Treating Insomnia on Behavioral Weight Loss Outcomes in Survivors of Breast Cancer | NIH | National Cancer Institute | 2023 to 2025 | $2,001,943 | July 1, 2023 | June 30, 2028 | WILDER COUGHLIN, JANELLE | reporter.nih.gov |
| Deciphering the Acidic Tumor Environment: A Phase I/IIa Study of Pre-Operative Multiparametric MRI and pHLIP® ICG Intra-Operative Fluorescence Imaging of Primary Breast Cancer | NIH | National Cancer Institute | 2023 to 2025 | $2,000,741 | March 1, 2023 | February 28, 2027 | MORROW, MONICA | reporter.nih.gov |
| Treg-depleting immunotherapy | NIH | National Cancer Institute | 2021 to 2022 | $2,000,000 | September 7, 2020 | September 30, 2024 | SUZDAK, PETER DAVID | reporter.nih.gov |
| Development of a Companion Diagnostic Assay for Detection of ADAM8-Positive Cancers | NIH | National Cancer Institute | 2022 to 2023 | $2,000,000 | September 1, 2022 | August 31, 2025 | SONENSHEIN, GAIL E. | reporter.nih.gov |
| Development of CD4 TCR-engineered T cell immunotherapy in triple-negative breast cancer | NIH | National Cancer Institute | 2024 to 2025 | $2,000,000 | September 20, 2024 | August 31, 2027 | WANG, YICHENG | reporter.nih.gov |
| At-home, ultrasonic device for treatment of vulvovaginal atrophy | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 to 2025 | $2,000,000 | September 1, 2024 | August 31, 2026 | ROCKWEILER, HOLLY | reporter.nih.gov |
| Everyday Use of Optical Cherenkov Imaging Identifies Adverse Events and Opportunities for Improved Radiation Treatment | NIH | National Cancer Institute | 2021 to 2022 | $1,999,995 | August 24, 2021 | July 31, 2024 | WARE, WILLIAM | reporter.nih.gov |
| Phase I Clinical Testing of a First-in-Class Therapy against Metastatic Cancer | NIH | National Cancer Institute | 2024 to 2025 | $1,999,972 | September 4, 2024 | August 31, 2026 | MEDAROVA, ZDRAVKA O | reporter.nih.gov |
| ATUSA: World's First Wearable and Automated 3D Breast Ultrasound System with AI | NIH | National Cancer Institute | 2024 to 2025 | $1,999,730 | September 6, 2024 | August 31, 2026 | SABERI, SHADI | reporter.nih.gov |
| Antibody-guided localized activation of bioorthogonal protodrugs via click chemistry | NIH | National Cancer Institute | 2023 to 2024 | $1,999,687 | September 1, 2023 | August 31, 2025 | MEJIA ONETO, JOSE M | reporter.nih.gov |
| An Open-Labeled, Single Arm Phase 2 Efficacy and Safety Study of REM-001 Photodynamic Therapy (PDT) for Treatment of Cutaneous Metastatic Breast Cancer (CMBC) | NIH | National Cancer Institute | 2023 to 2024 | $1,999,439 | July 1, 2023 | June 30, 2025 | BROWN, DENNIS | reporter.nih.gov |
| A treatment drug for triple negative breast cancer | NIH | National Cancer Institute | 2022 to 2023 | $1,999,124 | July 1, 2022 | June 30, 2024 | LIU, ZHI-REN | reporter.nih.gov |
| Topic 433: A Federated Data Platform for Developing Unbiased Breast Imaging AI | NIH | National Cancer Institute | 2022 | $1,998,738 | September 15, 2022 | September 14, 2024 | MINTZ, AARON | reporter.nih.gov |
| Understanding and addressing rejection of personalized cancer risk information | NIH | National Cancer Institute | 2023 to 2025 | $1,998,383 | August 1, 2023 | June 30, 2028 | SCHERER, LAURA D. | reporter.nih.gov |
| SBIR TOPIC 401 PHASE II: | NIH | National Cancer Institute | 2023 | $1,998,128 | September 18, 2023 | September 17, 2025 | GHAZI, PH.D., PEYMON | reporter.nih.gov |
| Spatial genomics analysis of tumor samples | NIH | National Cancer Institute | 2023 to 2024 | $1,996,962 | September 1, 2023 | August 31, 2025 | FRIEDA, KIRSTEN | reporter.nih.gov |
| Immunoengineering Next-Generation Cancer Therapies with Focused Ultrasound | NIH | Office of the Director, National Institutes of Health | 2021 to 2025 | $1,994,626 | September 14, 2021 | February 28, 2027 | SHEYBANI, NATASHA DIBA | reporter.nih.gov |
| Development of a cell-penetrating beta-catenin antagonist peptide as a therapeutic candidate for Wnt-driven breast cancer | NIH | National Cancer Institute | 2023 to 2024 | $1,994,379 | September 2, 2021 | April 30, 2025 | ROTOLO, JIM | reporter.nih.gov |
| Novel small molecules for protection against doxorubicin cardiotoxicity in TNBC | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $1,993,505 | May 16, 2022 | October 31, 2024 | SWINDLEHURST, CATHY A | reporter.nih.gov |
| Enabling effective anti-tumor immunity from targeted antibodies through dual innate and adaptive immune checkpoint blockade in non-immunogenic cancers | NIH | National Cancer Institute | 2021 to 2024 | $1,993,308 | December 6, 2019 | November 30, 2024 | HARTMAN, ZACHARY CONRAD | reporter.nih.gov |
| Developing an in vitro to in vivo pipeline of mammary gland exposure-response relationships to per- and poly-fluoroalkyl substances (PFAS) | NIH | National Institute of Environmental Health Sciences | 2021 to 2024 | $1,993,149 | September 28, 2020 | June 30, 2026 | OLDENBURG, AMY L | reporter.nih.gov |
| Phase 1a/1b Trial of Exercise Treatment in Hormone Receptor-Positive Metastatic Breast Cancer | NIH | National Cancer Institute | 2021 to 2023 | $1,990,761 | April 3, 2019 | March 31, 2024 | IYENGAR, NEIL MUKUND | reporter.nih.gov |
| Development of VNLG-152R as novel therapeutic for triple negative breast cancer | NIH | National Cancer Institute | 2021 to 2022 | $1,990,200 | August 1, 2021 | July 31, 2024 | RAMAMURTHY, VIDYA P | reporter.nih.gov |
| Regulation of DNA synthesis in response to DNA damage | NIH | National Cancer Institute | 2021 to 2025 | $1,988,550 | December 1, 2015 | November 30, 2025 | CICCIA, ALBERTO | reporter.nih.gov |
| A comprehensive imaging solution for dense breast cancer screening and diagnostics | NIH | National Cancer Institute | 2024 to 2025 | $1,988,177 | February 28, 2022 | June 30, 2027 | GHAZI, PEYMON | reporter.nih.gov |
| High-Resolution Breast MRI at 3.0T | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2023 | $1,988,003 | March 1, 2020 | November 30, 2024 | HARGREAVES, BRIAN ANDREW | reporter.nih.gov |
| Regulation of collagen linearization during cancer progression and metastasis | NIH | National Cancer Institute | 2021 to 2025 | $1,984,680 | July 20, 2020 | February 28, 2027 | LABELLE, MYRIAM | reporter.nih.gov |
| Blood-Based Biomarkers for Personalized Risk Assessment of Breast and Ovarian Cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,983,279 | September 1, 2023 | August 31, 2028 | FAHRMANN, JOHANNES F | reporter.nih.gov |
| Breast Cancer Brain Metastasis Therapy by Focused Ultrasound-Guided Control of HER2 CAR T cells | NIH | National Cancer Institute | 2023 to 2025 | $1,982,412 | June 8, 2023 | May 31, 2028 | ARVANITIS, KONSTANTINOS-COSTAS | reporter.nih.gov |
| Integrating genomic and transcriptomic data to identify breast cancer susceptibility genes | NIH | National Cancer Institute | 2021 to 2024 | $1,981,650 | July 1, 2019 | June 30, 2025 | ZHENG, WEI | reporter.nih.gov |
| Modeling Metastasis and Acquired Drug Resistance Using Circulating Tumor Cells | NIH | National Cancer Institute | 2021 to 2025 | $1,979,840 | April 1, 2008 | March 31, 2028 | HABER, DANIEL A. | reporter.nih.gov |
| The Role of Lung Resident Mesenchymal Stem Cells in Post-Chemotherapy Lung Metastases of Breast Cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,979,303 | February 4, 2020 | January 31, 2027 | REN, GUANGWEN | reporter.nih.gov |
| Role of gut microbe composition in psychosocial symptom response to exercise training in breast cancer survivors | NIH | National Cancer Institute | 2021 to 2025 | $1,978,441 | June 1, 2019 | November 30, 2026 | ROGERS, LAURA Q | reporter.nih.gov |
| Novobiocin-mediated polymerase theta inhibition in homologous recombination repair-deficient cancers | NIH | National Cancer Institute | 2022 to 2025 | $1,976,994 | September 1, 2022 | August 31, 2027 | SHAPIRO, GEOFFREY I. | reporter.nih.gov |
| Label-Free Optical Redox Imaging for Pretreatment Prognosis of Early-Stage Triple Negative Breast Cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,976,379 | September 19, 2023 | August 31, 2028 | LI, LIN Z | reporter.nih.gov |
| Mapping the single cell state basis of metastasis in space and time | NIH | National Cancer Institute | 2023 to 2025 | $1,975,464 | September 12, 2023 | August 31, 2028 | EWALD, ANDREW JOSEF | reporter.nih.gov |
| A recombinant matrix to improve autologous tissue grafts | NIH | National Cancer Institute | 2022 to 2023 | $1,972,696 | September 11, 2019 | June 30, 2025 | ROBERTS, STEFAN | reporter.nih.gov |
| Detection, Radiosensitization and Theranostic Targeting of Metastatic Breast Cancer by PTPmu | NIH | National Cancer Institute | 2023 to 2025 | $1,971,026 | December 1, 2022 | November 30, 2027 | BRADY-KALNAY, SUSANN M | reporter.nih.gov |
| Gasdermin E and pyroptosis in cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,970,899 | April 3, 2020 | March 31, 2025 | LIEBERMAN, JUDY | reporter.nih.gov |
| Study of Break-induced Replication in Mammalian Cells | NIH | National Cancer Institute | 2021 to 2024 | $1,970,649 | December 10, 2019 | November 30, 2025 | WU, XIAOHUA | reporter.nih.gov |
| Nanoparticle delivery of miRNA-based therapeutics to overcome clinical challenges in triple negative breast cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,969,673 | March 4, 2021 | February 28, 2027 | WANG, ZHIHUI | reporter.nih.gov |
| Copper-depleting nanotheranostics for treating triple negative breast cancer | NIH | National Cancer Institute | 2021 to 2023 | $1,968,063 | September 1, 2019 | August 31, 2025 | RAO, JIANGHONG | reporter.nih.gov |
| Mammary Epithelium Permeability, Lactation Outcomes, and Infant Health | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 to 2025 | $1,967,058 | August 11, 2023 | May 31, 2028 | ARCARO, KATHLEEN FRANCES | reporter.nih.gov |
| Convergent AI for Precise Breast Cancer Risk Assessment | NIH | National Cancer Institute | 2021 to 2024 | $1,967,056 | June 1, 2020 | May 31, 2025 | WONG, STEPHEN TC | reporter.nih.gov |
| Leveraging tumor registries and pathology specimens to facilitate genetic testing and traceback for ovarian cancer | NIH | National Cancer Institute | 2021 to 2023 | $1,967,027 | March 1, 2020 | February 28, 2025 | HUNTER, JESSICA EZZELL | reporter.nih.gov |
| Molecular mechanisms of estrogen receptor-dependent transcription regulation | NIH | National Cancer Institute | 2021 to 2023 | $1,965,781 | January 1, 2019 | March 31, 2024 | ROEDER, ROBERT G | reporter.nih.gov |
| Social networks and disparities in health behaviors and breast cancer outcomes in immigrant women | NIH | National Cancer Institute | 2021 to 2024 | $1,963,105 | July 1, 2019 | March 31, 2026 | KROENKE, CANDYCE H | reporter.nih.gov |
| Fruit and vegetable intervention in lactating women to reduce breast cancer risk: effects on breast cell DNA methylation, breast inflammation, and weight | NIH | National Cancer Institute | 2021 to 2023 | $1,962,503 | June 6, 2019 | May 31, 2025 | ARCARO, KATHLEEN FRANCES | reporter.nih.gov |
| Systemic delivery of an oncolytic adenovirus targeting TGFβ to enhance anti-PD-1 and anti-CTLA-4 therapy for triple negative breast cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,961,125 | March 1, 2021 | February 28, 2027 | XU, WEIDONG | reporter.nih.gov |
| Fluid mechanics approach to tissue perfusion quantification in MRI | NIH | National Institute of Biomedical Imaging and Bioengineering | 2023 to 2025 | $1,960,570 | August 1, 2023 | July 31, 2027 | WANG, YI | reporter.nih.gov |
| Advancing Photoacoustic Tomography in breast imaging to predict response in breast cancers treated with neoadjuvant therapy | NIH | National Cancer Institute | 2023 to 2025 | $1,960,318 | July 3, 2023 | June 30, 2028 | LAI, LILY LAU | reporter.nih.gov |
| Homologous recombination repair capacity in peripheral blood lymphocytes as a breast cancer risk factor | NIH | National Cancer Institute | 2023 to 2025 | $1,958,719 | September 1, 2022 | August 31, 2027 | ZHAO, HUA | reporter.nih.gov |
| Understanding lactate catabolism by BACH1 in triple negative breast cancer | NIH | National Cancer Institute | 2022 to 2025 | $1,957,607 | August 1, 2022 | July 31, 2027 | LEE, JIYOUNG | reporter.nih.gov |
| BBOX1 is a Novel Oncogenic Driver in Triple Negative Breast Cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,955,255 | April 15, 2021 | March 31, 2026 | ZHANG, QING | reporter.nih.gov |
| Long-Term Trajectories of Accelerated Biological Aging and Functional Decline Associated with Breast Cancer and its Treatment | NIH | National Cancer Institute | 2023 to 2025 | $1,947,928 | September 1, 2023 | August 31, 2028 | FELICIANO, ELIZABETH MARJORIE CESPEDES | reporter.nih.gov |
| Functions of ductal- and stromal-associated macrophages in the mammary gland | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2025 | $1,945,818 | September 7, 2022 | July 31, 2027 | MACHADO, HEATHER L | reporter.nih.gov |
| Defining BRCA replication dysfunction in therapy response | NIH | National Cancer Institute | 2021 to 2025 | $1,945,815 | June 12, 2020 | May 31, 2026 | CANTOR, SHARON B | reporter.nih.gov |
| STARLIGHT, The Next Generation X-ray Imaging Technology | NIH | National Cancer Institute | 2022 to 2023 | $1,942,984 | September 15, 2022 | December 31, 2024 | SILVER, ERIC | reporter.nih.gov |
| Modulation of Epigenetic Target in the Bone to Treat Breast Cancer Metastasis | NIH | National Cancer Institute | 2023 to 2025 | $1,937,652 | July 3, 2023 | June 30, 2028 | XIAO, HAN | reporter.nih.gov |
| Multicenter trial of decision support for breast cancer chemoprevention | NIH | National Cancer Institute | 2021 to 2023 | $1,934,358 | December 1, 2018 | November 30, 2024 | CREW, KATHERINE D | reporter.nih.gov |
| Individualized medicine to predict and prevent chemotherapy-related heart failure | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,934,221 | July 1, 2023 | November 30, 2026 | NORTON, NADINE | reporter.nih.gov |
| Developing a novel combination immunotherapy for triple-negative breast cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,933,835 | September 18, 2023 | August 31, 2028 | UENO, NAOTO T. | reporter.nih.gov |
| UBR5's mechanisms of action in tumorigenesis and immunoregulation | NIH | National Cancer Institute | 2023 to 2025 | $1,932,924 | March 1, 2023 | February 29, 2028 | MA, XIAOJING | reporter.nih.gov |
| Next Gen Targeted nanoparticles for Inhibiting Gli2 in Bone Metastatic Tumors | NIH | National Cancer Institute | 2023 to 2025 | $1,932,125 | June 1, 2023 | May 31, 2027 | RHOADES (STERLING), JULIE A | reporter.nih.gov |
| Optimizing psychosocial intervention for breast cancer-related sexual morbidity: A factorial trial using the National Cancer Institute Community Oncology Research Program (NCORP) network | NIH | National Cancer Institute | 2023 to 2025 | $1,932,089 | January 19, 2023 | December 31, 2027 | SHAFFER, KELLY MCLEAN | reporter.nih.gov |
| AI enhanced lifetime-based mesoscopic in vivo imaging of tissue molecular heterogeneity | NIH | National Cancer Institute | 2023 to 2025 | $1,930,934 | June 1, 2023 | May 31, 2028 | INTES, XAVIER | reporter.nih.gov |
| Defining the Critical Function and Regulation of NNMT in Breast Cancer Progression and Metastasis | NIH | National Cancer Institute | 2021 to 2025 | $1,929,914 | April 1, 2021 | March 31, 2027 | ZHOU, BINHUA P | reporter.nih.gov |
| Measuring cellular senescence to predict and prevent peripheral neuropathy | NIH | National Institute on Aging | 2021 to 2023 | $1,928,919 | September 15, 2021 | August 31, 2025 | MITIN, NATALIA | reporter.nih.gov |
| Effect of tumor cell glutamine metabolism on anti-tumor immunity in TNBC | NIH | National Cancer Institute | 2021 to 2024 | $1,928,321 | July 17, 2020 | June 30, 2025 | CHEN, JIN | reporter.nih.gov |
| Mitochondrial iron export therapy for doxorubicin-induced cardiotoxicity | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,921,021 | January 1, 2023 | December 31, 2026 | KIM, JONGHAN | reporter.nih.gov |
| Mechanisms governing metastatic dormancy and reactivation | NIH | National Cancer Institute | 2021 to 2022 | $1,915,493 | August 1, 2016 | July 31, 2023 | GIANCOTTI, FILIPPO G | reporter.nih.gov |
| FOOD (Food to Overcome Outcomes Disparities) | NIH | National Cancer Institute | 2021 to 2023 | $1,915,218 | June 1, 2018 | May 31, 2025 | GANY, FRANCESCA M | reporter.nih.gov |
| Synthetic lethality by targeting the core senescent mechanism in lung cancer. | NIH | National Cancer Institute | 2021 to 2024 | $1,914,409 | February 1, 2020 | January 31, 2025 | WANG, XIAO-FAN | reporter.nih.gov |
| SRC-3/PELP1 complexes drive stem-like phenotypes in luminal breast cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,913,946 | December 1, 2019 | November 30, 2025 | LANGE, CAROL A | reporter.nih.gov |
| To study the EMT contributions in tumor metastasis and chemoresistance by using lineage tracing models | NIH | National Cancer Institute | 2021 to 2024 | $1,912,019 | July 17, 2020 | June 30, 2026 | GAO, DINGCHENG | reporter.nih.gov |
| Dual targeting of PI3K and NOS pathways in Metaplastic BreastCancer (MBC) | NIH | National Cancer Institute | 2023 to 2025 | $1,910,419 | July 8, 2023 | June 30, 2028 | CHANG, JENNY C-N | reporter.nih.gov |
| Leveraging the GTP Biosynthetic Pathway for Anti-Tumor Therapies | NIH | National Cancer Institute | 2021 to 2025 | $1,906,679 | December 10, 2020 | April 30, 2026 | BIANCHI-SMIRAGLIA, ANNA | reporter.nih.gov |
| Impact of hypoxia on lipid metabolism in obesity-driven breast cancer progression | NIH | National Cancer Institute | 2023 to 2025 | $1,906,569 | December 28, 2022 | November 30, 2027 | TEEGARDEN, DOROTHY | reporter.nih.gov |
| Flexible NLP toolkit for automatic curation of outcomes for breast cancer patients | NIH | National Cancer Institute | 2022 to 2025 | $1,905,455 | August 1, 2022 | July 31, 2027 | BANERJEE, IMON | reporter.nih.gov |
| Synergistic Targeted Therapy of Antibody-Drug Conjugates for Triple-Negative Breast Cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,905,044 | January 1, 2020 | February 28, 2026 | LIU, RUNHUA RUNA | reporter.nih.gov |
| Polygenic Risk Prediction of Breast Cancer for Women of African Descent | NIH | National Cancer Institute | 2021 to 2025 | $1,904,511 | April 19, 2018 | July 1, 2028 | HUO, DEZHENG | reporter.nih.gov |
| Chip-Scale Intraoperative Optical Navigation with Immunotargeted Upconverting Nanoparticles | NIH | National Cancer Institute | 2023 to 2025 | $1,900,633 | June 15, 2023 | May 31, 2027 | ANWAR, MEKHAIL | reporter.nih.gov |
| Targeting of a Major Immune Evasion Pathway in Triple-negative Breast Cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,897,891 | August 1, 2020 | April 30, 2026 | WUCHERPFENNIG, KAI W | reporter.nih.gov |
| Understanding the role of DNA damage repair in racial disparities of triple-negative breast cancer outcomes | NIH | National Cancer Institute | 2022 to 2025 | $1,897,523 | February 3, 2022 | January 31, 2027 | SHAO, JIEYA | reporter.nih.gov |
| Evaluation of Commercial Mammography-Based Artificial Intelligence Algorithms for Breast Cancer Risk Prediction in U.S. Screening Populations | NIH | National Cancer Institute | 2024 to 2025 | $1,890,145 | September 9, 2024 | August 31, 2029 | LOWRY, KATHRYN PAIGE | reporter.nih.gov |
| Assessing DNA polymerase theta as a therapeutic target in BRCA1 mutant cancer | NIH | National Cancer Institute | 2022 to 2025 | $1,890,097 | March 1, 2022 | February 28, 2027 | JOHNSON, NEIL | reporter.nih.gov |
| Matrix density promotes pro-tumorigenic hormone actions in breast cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,888,655 | April 1, 2014 | June 30, 2026 | SCHULER, LINDA A. | reporter.nih.gov |
| Targeting Neoantigens in Triple Negative Breast Cancer | NIH | National Cancer Institute | 2021 to 2023 | $1,888,069 | August 1, 2019 | July 31, 2025 | GILLANDERS, WILLIAM E. | reporter.nih.gov |
| Regulation of resistance to CDK4/6 inhibitor in breast cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,886,706 | March 22, 2023 | February 29, 2028 | ZHU, WENGE | reporter.nih.gov |
| RNase H2 is a novel therapeutic target in triple negative breast cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,886,006 | July 1, 2021 | June 30, 2027 | LIN, SHIAW-YIH | reporter.nih.gov |
| Prognostic analysis and progression modeling of basal-like breast cancer using multi-region sequencing | NIH | National Cancer Institute | 2023 to 2025 | $1,885,471 | June 9, 2023 | May 31, 2028 | SUN, YIJUN | reporter.nih.gov |
| A Wholly Protein-based Self-assembly Nanoplatform for TNBC-specific Combination Therapy | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2025 | $1,885,144 | August 1, 2022 | April 30, 2027 | LIU, RIHE | reporter.nih.gov |
| Development of an ultrasound detectable, migration-resistant biopsy marker for improving care in patients with breast cancer | NIH | National Institute of Biomedical Imaging and Bioengineering | 2023 to 2025 | $1,884,589 | December 15, 2022 | November 30, 2026 | URBAN, MATTHEW WILLIAM | reporter.nih.gov |
| Local Services Navigation to Improve Breast Cancer Screening Outcomes | NIH | National Cancer Institute | 2023 to 2025 | $1,882,771 | July 25, 2023 | June 30, 2028 | OZANNE, ELISSA MARY | reporter.nih.gov |
| A nested case-control study of perfluoroalkyl and polyfluoroalkyl substances (PFAS) and breast cancer risk in the Multiethnic Cohort | NIH | National Cancer Institute | 2023 to 2025 | $1,882,745 | April 26, 2023 | March 31, 2028 | LEE, EUNJUNG | reporter.nih.gov |
| Novel Role of ThPOK in Mammary Carcinoma | NIH | National Cancer Institute | 2021 to 2023 | $1,880,700 | April 3, 2019 | March 31, 2025 | KAPPES, DIETMAR J | reporter.nih.gov |
| Dual-pronged nano-drug delivery using plant virus-like particles | NIH | National Cancer Institute | 2021 to 2025 | $1,880,163 | September 15, 2022 | August 31, 2027 | STEINMETZ, NICOLE FRANZISKA | reporter.nih.gov |
| Next generation deep tissue quantitative optical imaging | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2024 | $1,877,447 | January 1, 2021 | December 31, 2025 | OSULLIVAN, THOMAS D | reporter.nih.gov |
| Impact of cancer predisposition on oncogenic process, microenvironment, and treatment | NIH | National Cancer Institute | 2022 to 2025 | $1,877,290 | January 1, 2022 | December 31, 2026 | DING, LI | reporter.nih.gov |
| Population-Based Evaluation of Artificial Intelligence for Mammography Prior to Widespread Clinical Translation | NIH | National Cancer Institute | 2022 to 2024 | $1,875,613 | July 1, 2022 | June 30, 2027 | LEE, CHRISTOPH I | reporter.nih.gov |
| Estrogen Receptor and NFkB Crosstalk in Breast Cancer | NIH | National Cancer Institute | 2022 to 2025 | $1,874,537 | December 4, 2015 | January 31, 2027 | COLOFF, JONATHAN L. | reporter.nih.gov |
| INTEGRATING OMICS AND QUANTITATIVE IMAGING DATA IN CO-CLINICAL TRIALS TO PREDICT TREATMENT RESPONSE IN TRIPLE NEGATIVE BREAST CANCER | NIH | National Cancer Institute | 2021 to 2023 | $1,873,363 | September 19, 2019 | August 31, 2025 | LEWIS, MICHAEL T. | reporter.nih.gov |
| Reversing Drug Resistance in Tumors with Clickable Antibody Pairs | NIH | National Cancer Institute | 2023 to 2025 | $1,869,482 | January 1, 2023 | December 31, 2027 | RIBEIRO PEREIRA, PATRICIA MANUELA | reporter.nih.gov |
| Mechanism of LSD1 in breast cancer metastasis suppression | NIH | National Cancer Institute | 2021 to 2025 | $1,868,496 | December 1, 2020 | November 30, 2025 | LI, ZHE | reporter.nih.gov |
| Three-Arm randomized trial comparing the effect of aspirin, sulindac or no treatment control on breast density in patients with elevated breast cancer risk | NIH | National Cancer Institute | 2022 to 2024 | $1,867,258 | September 20, 2019 | February 28, 2026 | THOMPSON, PATRICIA ANN | reporter.nih.gov |
| Immunometabolic pathways enabled by PARP inhibition in breast cancer | NIH | National Cancer Institute | 2022 to 2025 | $1,866,725 | July 1, 2022 | June 30, 2027 | GUERRIERO, JENNIFER L. | reporter.nih.gov |
| Novel therapeutics for targeting checkpoint dysfunction in cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,865,672 | December 15, 2016 | January 31, 2027 | LIN, WEEI-CHIN | reporter.nih.gov |
| ERa is a novel RNA-binding protein controlling breast cancer | NIH | National Cancer Institute | 2022 to 2025 | $1,863,376 | March 1, 2022 | February 28, 2027 | RUGGERO, DAVIDE | reporter.nih.gov |
| Defining genetic and metabolic requirements of aggressive breast cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,861,232 | April 1, 2020 | March 31, 2026 | WALTZ, SUSAN E | reporter.nih.gov |
| Aging-associated mammary cancer-initiating cells | NIH | National Cancer Institute | 2021 to 2025 | $1,860,500 | September 17, 2021 | August 31, 2026 | SUN, LUZHE | reporter.nih.gov |
| Novel immune suppressive activities of Fas/CD95 in triple negative breast cancer | NIH | National Cancer Institute | 2022 to 2025 | $1,859,187 | July 7, 2022 | June 30, 2027 | PETER, MARCUS E. | reporter.nih.gov |
| Long-Term Adverse Outcomes Among Rural Cancer Survivors in a Population-Based Cohort | NIH | National Cancer Institute | 2021 to 2024 | $1,858,613 | July 16, 2020 | June 30, 2025 | CAMP, NICOLA J. | reporter.nih.gov |
| DNA replication stress in cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,858,597 | August 1, 2019 | February 28, 2029 | VINDIGNI, ALESSANDRO | reporter.nih.gov |
| Hepatic steatosis promotes liver metastasis | NIH | National Cancer Institute | 2022 to 2025 | $1,857,013 | January 1, 2022 | November 30, 2026 | ROHATGI, NIDHI | reporter.nih.gov |
| Therapeutic enzyme depletion of L-serine for cancer treatment | NIH | National Cancer Institute | 2023 to 2025 | $1,854,318 | April 1, 2023 | March 31, 2028 | STONE, EVERETT | reporter.nih.gov |
| The regulation of cancer and aging by methionine | NIH | National Institute on Aging | 2023 to 2025 | $1,852,002 | July 1, 2023 | March 31, 2028 | LAMMING, DUDLEY WILLIAM | reporter.nih.gov |
| Programmable encapsulation systems to improve delivery of therapeutic bacteria | NIH | National Institute of Biomedical Imaging and Bioengineering | 2023 to 2025 | $1,851,261 | August 1, 2023 | July 31, 2027 | DANINO, TAL | reporter.nih.gov |
| Molecular origins and impact of APOBEC3 mutagenesis in cancer | NIH | National Cancer Institute | 2022 to 2025 | $1,850,023 | September 1, 2022 | August 31, 2027 | MACIEJOWSKI, JOHN | reporter.nih.gov |
| A Mobile TXT-based Intervention to Improve Adherence to Adjuvant Hormone Therapy and Symptom Management for BCa Survivors | NIH | National Cancer Institute | 2021 to 2023 | $1,847,981 | June 11, 2019 | May 31, 2025 | WEN, KUANG-YI | reporter.nih.gov |
| Non-canonical roles of Mitotic Arrest Deficient 1 (Mad1) in tumor promotion | NIH | National Cancer Institute | 2022 to 2025 | $1,846,640 | April 1, 2022 | March 31, 2027 | WEAVER, BETH A | reporter.nih.gov |
| Taking AIM at Breast Cancer: Targeting Adiposity and Inflammation with Movement to Improve Prognosis in Breast Cancer Survivors | NIH | National Cancer Institute | 2021 to 2023 | $1,845,213 | September 1, 2018 | August 31, 2025 | DIELI-CONWRIGHT, CHRISTINA | reporter.nih.gov |
| Emerging Strategies for Therapy of Metastatic Brain Cancer | NIH | National Cancer Institute | 2024 to 2025 | $1,843,587 | August 1, 2024 | July 31, 2031 | LESNIAK, MACIEJ S | reporter.nih.gov |
| Multicenter Quantitative MRI Assessment of Breast Cancer Therapy Response | NIH | National Cancer Institute | 2021 to 2024 | $1,843,207 | December 1, 2020 | October 5, 2024 | HUANG, WEI | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| Univ of North Carolina Chapel Hill | Chapel Hill, NC | 58 | $95.3 million | 0 | $0 |
| Washington University | Saint Louis, MO | 45 | $92.1 million | 0 | $0 |
| Sloan-Kettering Inst Can Research | New York, NY | 46 | $69.4 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 58 | $68.3 million | 0 | $0 |
| University of TX MD Anderson Can CTR | Houston, TX | 67 | $62.4 million | 0 | $0 |
| Dana-Farber Cancer Inst | Boston, MA | 34 | $52.1 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 43 | $51.2 million | 0 | $0 |
| Columbia University Health Sciences | New York, NY | 35 | $51.1 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 50 | $49.5 million | 0 | $0 |
| Stanford University | Stanford, CA | 40 | $47.8 million | 0 | $0 |
| Baylor College of Medicine | Houston, TX | 43 | $47 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 47 | $42.6 million | 0 | $0 |
| Ohio State University | Columbus, OH | 36 | $42.6 million | 0 | $0 |
| University of Kansas Medical Center | Kansas City, KS | 9 | $40.7 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 37 | $40 million | 0 | $0 |
| University of Wisconsin-Madison | Madison, WI | 30 | $39.2 million | 0 | $0 |
| University of Washington | Seattle, WA | 29 | $39 million | 0 | $0 |
| Duke University | Durham, NC | 38 | $38.5 million | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 39 | $36.7 million | 0 | $0 |
| Mayo Clinic Rochester | Rochester, MN | 26 | $33.5 million | 0 | $0 |
| Roswell Park Cancer Institute Corp | Buffalo, NY | 34 | $33.1 million | 0 | $0 |
| Georgetown University | Washington, DC | 22 | $32.1 million | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 35 | $31.5 million | 0 | $0 |
| Emory University | Atlanta, GA | 33 | $31 million | 0 | $0 |
| Sanford Burnham Prebys Medical Discovery Institute | La Jolla, CA | 8 | $30.9 million | 0 | $0 |
| Northwestern University at Chicago | Chicago, IL | 31 | $30.2 million | 0 | $0 |
| Kaiser Foundation Research Institute | Oakland, CA | 12 | $30.2 million | 0 | $0 |
| Vanderbilt University Medical Center | Nashville, TN | 19 | $30 million | 0 | $0 |
| Fred Hutchinson Cancer Center | Seattle, WA | 24 | $29.8 million | 0 | $0 |
| H. Lee Moffitt Cancer CTR & Res Inst | Tampa, FL | 23 | $27.5 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 32 | $27 million | 0 | $0 |
| Beth Israel Deaconess Medical Center | Boston, MA | 26 | $26.9 million | 0 | $0 |
| University of Colorado Denver | Aurora, CO | 33 | $26.1 million | 0 | $0 |
| Case Western Reserve University | Cleveland, OH | 24 | $25.8 million | 0 | $0 |
| University of Virginia | Charlottesville, VA | 23 | $25.3 million | 0 | $0 |
| University of Utah | Salt Lake City, UT | 27 | $25.1 million | 0 | $0 |
| University of Chicago | Chicago, IL | 21 | $24.9 million | 0 | $0 |
| University of Illinois at Chicago | Chicago, IL | 29 | $24.7 million | 0 | $0 |
| Icahn School of Medicine at Mount Sinai | New York, NY | 25 | $24.5 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 23 | $24.5 million | 0 | $0 |
| New York University School of Medicine | New York, NY | 20 | $23.6 million | 0 | $0 |
| Wayne State University | Detroit, MI | 10 | $23 million | 0 | $0 |
| University of Alabama at Birmingham | Birmingham, AL | 24 | $22.4 million | 0 | $0 |
| Virginia Commonwealth University | Richmond, VA | 29 | $22.1 million | 0 | $0 |
| Ut Southwestern Medical Center | Dallas, TX | 21 | $22 million | 0 | $0 |
| University of California at Davis | Davis, CA | 25 | $21.8 million | 0 | $0 |
| University of Illinois at Urbana-Champaign | Urbana, IL | 18 | $21.3 million | 0 | $0 |
| University of Minnesota | Minneapolis, MN | 22 | $20.9 million | 0 | $0 |
| Boston University Medical Campus | Boston, MA | 11 | $20.9 million | 0 | $0 |
| Methodist Hospital Research Institute | Houston, TX | 14 | $20 million | 0 | $0 |
| University of Arizona | Tucson, AZ | 13 | $18.9 million | 0 | $0 |
| Yale University | New Haven, CT | 23 | $18.9 million | 0 | $0 |
| Harvard University D/b/a Harvard School of Public Health | Boston, MA | 6 | $18.6 million | 0 | $0 |
| Beckman Research Institute/city of Hope | Duarte, CA | 16 | $18.3 million | 0 | $0 |
| Univ of Arkansas for Med Scis | Little Rock, AR | 8 | $18.2 million | 0 | $0 |
| Georgia Tech Research Corporation | Atlanta, GA | 11 | $18.1 million | 0 | $0 |
| University of Tennessee Health Sci CTR | Memphis, TN | 12 | $17.9 million | 0 | $0 |
| Indiana University Indianapolis | Indianapolis, IN | 17 | $17.4 million | 0 | $0 |
| University of Iowa | Iowa City, IA | 10 | $17.1 million | 0 | $0 |
| Oregon Health & Science University | Portland, OR | 14 | $16.5 million | 0 | $0 |
| Fred Hutchinson Cancer Research Center | Seattle, WA | 20 | $16.5 million | 0 | $0 |
| University of Southern California | Los Angeles, CA | 12 | $16.4 million | 0 | $0 |
| SUNY at Buffalo | Amherst, NY | 8 | $16 million | 0 | $0 |
| University of California-Irvine | Irvine, CA | 13 | $15.9 million | 0 | $0 |
| University of Texas at Austin | Austin, TX | 15 | $15.7 million | 0 | $0 |
| Thomas Jefferson University | Philadelphia, PA | 13 | $15.5 million | 0 | $0 |
| University of Texas HLTH Science Center | San Antonio, TX | 17 | $15.3 million | 0 | $0 |
| SUNY at Stony Brook | Stony Brook, NY | 13 | $15.2 million | 0 | $0 |
| Michigan State University | East Lansing, MI | 10 | $15 million | 0 | $0 |
| Medical College of Wisconsin | Milwaukee, WI | 17 | $14.8 million | 0 | $0 |
| University of California Los Angeles | Los Angeles, CA | 17 | $14.2 million | 0 | $0 |
| University of Florida | Gainesville, FL | 17 | $14 million | 0 | $0 |
| Medical University of South Carolina | Charleston, SC | 17 | $14 million | 0 | $0 |
| George Washington University | Washington, DC | 11 | $13.7 million | 0 | $0 |
| University of Hawaii | Honolulu, HI | 7 | $13.6 million | 0 | $0 |
| Jackson Laboratory | Bar Harbor, ME | 9 | $13.3 million | 0 | $0 |
| University of Maryland Baltimore | Baltimore, MD | 13 | $12.9 million | 0 | $0 |
| Albert Einstein College of Medicine | Bronx, NY | 14 | $12.9 million | 0 | $0 |
| University of Massachusetts Amherst | Amherst, MA | 12 | $12.8 million | 0 | $0 |
| Louisiana State University | Baton Rouge, LA | 4 | $12.2 million | 0 | $0 |
| Cedars-Sinai Medical Center | Los Angeles, CA | 11 | $11.3 million | 0 | $0 |
| Research Inst of Fox Chase Can CTR | Philadelphia, PA | 9 | $11.2 million | 0 | $0 |
| Cornell University | Ithaca, NY | 15 | $11 million | 0 | $0 |
| Univ of Massachusetts Med SCH Worcester | Worcester, MA | 16 | $11 million | 0 | $0 |
| University of Kentucky | Lexington, KY | 13 | $11 million | 0 | $0 |
| Dartmouth College | Hanover, NH | 14 | $11 million | 0 | $0 |
| University of Miami School of Medicine | Coral Gables, FL | 11 | $10.9 million | 0 | $0 |
| University of Texas HLTH Sci CTR Houston | Houston, TX | 10 | $10.9 million | 0 | $0 |
| Purdue University | West Lafayette, IN | 10 | $10.8 million | 0 | $0 |
| Vanderbilt University | Nashville, TN | 22 | $10.7 million | 0 | $0 |
| Rutgers Biomedical and Health Sciences | Newark, NJ | 15 | $10.6 million | 0 | $0 |
| University of Notre Dame | Notre Dame, IN | 9 | $10.5 million | 0 | $0 |
| Mayo Clinic Jacksonville | Jacksonville, FL | 7 | $10.4 million | 0 | $0 |
| University of Cincinnati | Cincinnati, OH | 8 | $9.9 million | 0 | $0 |
| Wake Forest University Health Sciences | Winston-Salem, NC | 12 | $9.5 million | 0 | $0 |
| University of Vermont & ST Agric College | Burlington, VT | 7 | $9.2 million | 0 | $0 |
| West Virginia University Research Corporation | Morgantown, WV | 14 | $9 million | 0 | $0 |
| Boise State University | Boise, ID | 2 | $8.6 million | 0 | $0 |
| University of Rochester | Rochester, NY | 10 | $8.3 million | 0 | $0 |
| Cleveland Clinic Lerner Com-Cwru | Cleveland, OH | 8 | $7.7 million | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 1,171 | $613,314,449 | 0 | $0 |
| 2024 | 1,323 | $591,174,738 | 0 | $0 |
| 2023 | 1,370 | $620,331,334 | 0 | $0 |
| 2022 | 1,342 | $583,479,898 | 0 | $0 |
| 2021 | 1,344 | $575,618,567 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.